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DRUGS ON TAP: MANAGING
PHARMACEUTICALS IN OUR NATION'S
WATERS
GABRIEL ECKSTEIN*
Pharmaceuticals in the environment and public water
supplies are believed to have serious impacts on human and
environmental health. Current research suggests that exposure to
certain drugs and their residues may result in a variety of adverse
human health effects. Other studies more conclusively show that
even minute concentrations ofpharmaceuticals in the environment
can have detrimental effects on aquatic and terrestrial species.
Unfortunately, the cost of removing these pernicious substances is
out of the financial reach of most municipalities and wastewater
and drinking water treatment operators.
Despite the concerns, little effort has been made to develop
broad management, mitigatory, or disposal prevention strategies
to address the potential threat from medications and their residues
in the environment or in our drinking water. Neither the United
States federal government nor the states have been able to
formulate an adequate response.
The purpose of this Article is to further awareness about the
lack of governmental attention to the growing problem
pharmaceuticals and pharmaceutical residues pose to the
environment and the nation's freshwater supplies. After describing
the scope of the problem, as well as the deficiencies and loopholes
in the existing statutory and regulatory regime, the Article
contends that focusing regulations on pharmaceuticals once they
reach the waste stream is an inadequate and ineffective approach
to reducing pharmaceutical pollutants in the environment. Rather,
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federal and state governments should implement mechanisms that
target the earlier lifecycle stages of pharmaceuticals so as to
prevent pharmaceuticals and their residues from reaching the
natural environment and, thereby, to reduce the risks to people,
communities, species, and ecosystems.
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INTRODUCTION
"Doctors prescribe hydrocodone for pain. They recommend
ranitidine for acid reflux, a diuretic called hydrochlorothiazide
for congestive heart failure. But you don't need a prescription
to get these drugs in tiny doses. They're found already in our
nation's water supply .... "I
In recent years, serious questions have been raised about the
environmental and health impacts of pharmaceuticals 2 in our
nation's fresh water resources.3 Numerous studies intimate that
unintended exposure to certain drugs, such as antibiotics and
endocrine disruptors, or a synergistic combination of
pharmaceutical substances, may cause adverse health impacts for
humans;4 other research has more conclusively established that
even minute concentrations of certain drugs can have detrimental
effects on aquatic and terrestrial species.5
I Dawn Fallik, This New Study Found More Drugs in Our Drinking Water
Than Anybody Knew-And No One's Doing Anything About It, NEW REPUBLIC
(Dec. 11, 2013), http://www.newrepublic.com/article/l 15883/drugs-drinking-
water-new-epa-study-finds-more-we-knew.
2 Pharmaceuticals encompass all synthetic and natural substances, both
prescription and over-the-counter, used in diagnosing, treating, altering, and
preventing disease. They are also used to manage the structure and functioning
of the human body as well as in veterinary activities. Christian G. Daughton &
Thomas A. Temes, Pharmaceuticals and Personal Care Products in the
Environment: Agents of Subtle Change?, 107 ENVTL. HEALTH PERSP. 907, 908
(1999). When discussing trace environmental contamination resulting from
human and animal drug use, the residual molecular entity or active
pharmaceutical ingredient is the thing being measured or referenced. See
Christian Daughton, Pharmaceuticals in the Environment. Sources and Their
Management, in 62 COMPREHENSIVE ANALYTICAL CHEMISTRY: ANALYSIS,
REMOVAL, EFFECTS AND RISK OF PHARMACEUTICALS IN THE WATER CYCLE
OCCURRENCE AND TRANSFORMATION IN THE ENVIRONMENT 44 (Mira Petrovic et
al. eds., 2013) [hereinafter Daughton, Pharmaceuticals in the Environment].
3 For example, in 2008, the Associated Press released a series of
investigative reports. AN AP INVESTIGATION: PHARMACEUTICALS FOUND IN
DRINKING WATER, http://hosted.ap.org/specials/interactives/pharmawater-site/
(last visited Mar. 23, 2014). These reports were distributed in print and
electronic media worldwide. See, e.g., Jeff Donn, Drug Traces Turn up in
Source Waters for Nation's Biggest City, ASSOCIATED PRESS (Mar.
2008), http://hosted.ap.org/specials/interactives/pharmawater site/dayl_02.html;
Martha Mendoza, On Eve of Hearings, White House Documents Show Feds
Failing to Take Action on Drugs in Water, ASSOCIATED PRESS (Apr. 13, 2006),
http://hosted.ap.org/specials/interactives/pharmawater site/april 13.html.
4 See infra notes 43-52 and accompanying text.
5 See Gabriel Eckstein & George William Sherk, Alternative Strategies for
Addressing the Presence and Effects of Pharmaceutical and Personal Care
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In addition, the various medications, pharmaceutical products,
and their residues, metabolites, and components (collectively
"pharmaceutical pollutants") that end up in the environment have
received growing attention from the fresh water treatment and
wastewater discharge communities because of their ability to
persist, or only partially degrade, in nature as well as during
freshwater and wastewater treatment. 6  Treating for these
substances after they enter the sewage or wastewater system or the
environment is costly and out of the financial reach of most
municipalities and wastewater and drinking water treatment
operators. 7 As a result, communities, health care professionals, and
environmental professionals are concerned about the ability of
municipalities to ensure safe freshwater for their residents and for
the surrounding environment.8
Despite the concerns, little effort has been made to develop
broad management, mitigatory, or disposal prevention strategies to
address the presence of pharmaceutical waste in the environment.
On the national level, Congress has not adopted legislation
specifically intended to address the multitude of pharmaceutical
pollutants that enter the natural environment or the threat they
pose to people and the environment. While certain
pharmaceuticals and pharmaceutical wastes 9 are haphazardly
Products in Fresh Water Resources, 15 DENVER WATER L. REV. 369 (2012)
(surveying the growing scientific evidence on the threats that Pharmaceuticals
and Personal Care Products (PPCPs) pose to people and the environment and
describing the confusing regulatory regime applicable to such substances); see
also infra notes 53-61 and accompanying text.
6 See Eckstein & Sherk, supra note 5 at 371-72; see also Kelly A.
Reynolds, Concern of Pharmaceuticals in Drinking Water, 50 WATER
CONDITIONING & PURIFICATION (2008) (noting that certain pharmaceuticals-
e.g., antibiotics and estrogens-may "persist in the environment either due to
their inability to biodegrade naturally or to their constant use keeping them ever-
present").
7 See infra note 183 and accompanying text.
8 See e.g., WORLD HEALTH ORG., PHARMACEUTICALS IN DRINKING WATER
15 (2012); Jeff Donn et al., Pharmawater 1: Pharmaceuticals Found in Drinking
Water, Affecting Wildlife and Maybe Humans, ASSOCIATED PRESS (Mar. 9,
2008), http://hosted.ap.org/specials/interactives/pharmawater-site/dayl_01 .html;
Matt Harvey, Your Tap Water Is Probably Laced with Antidepressants, SALON
(Mar. 14, 2013), http://www.salon.com/2013/03/14/your tapwater is
probablylaced_withanti depressants-partner/; David Noble, Trouble at the
Tap, WATER QUALITY PRODUCTS (Feb. 6. 2014), http://www.wqpmag.com/
trouble-tap.
9 Although there is no federal statutory or regulatory definition for
pharmaceutical waste, the term refers to pharmaceutical products that have been
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subject to a few statutory and regulatory mechanisms,' 0 they are,
for the most part, outside the scope of the law.
The purpose of this Article is to bring attention to the lack of
governmental focus on the growing problem posed by
pharmaceutical pollutants in the environment and the nation's
freshwater supplies. Section I describes how substances in rivers,
lakes, aquifers, and soils threaten the health of various species,
ecosystems, and people. Sections II and III review the existing
statutory and regulatory mechanisms applicable to pharmaceutical
pollutants, at both the federal and state levels, and identify the
loopholes and other deficiencies that make the existing system
inadequate and often irrelevant. Section IV concludes that a
targeted governmental response is critically necessary to reduce
existing known threats as well as minimize potential hazards. In
particular, this Section argues that mechanisms that prevent
pharmaceuticals from reaching the natural environment would be
more effective and appropriate approaches for reducing the risks
posed by pharmaceutical pollutants than the present system, which
intentionally or unintentionally discarded and have entered the waste stream. The
Missouri Department of Natural Resources described pharmaceutical waste as
discarded or confiscated pharmaceutical items that include pharmaceutical
products, illegal drugs, and pharmaceutical precursors or ingredients. MO. DEP'T
OF NATURAL RES., IS YOUR PHARMACEUTICAL WASTE ALSO HAZARDOUS
WASTE?, HAZARDOUS WASTE PROGRAM FACT SHEET (2010), available at
https://www.dnr.mo.gov/pubs/pub2128.htm. The Wisconsin Department of
Natural Resources identifies pharmaceutical waste as including expired drugs,
patients' discarded personal medications, waste materials containing excess
drugs (syringes, IV bags, tubing, vials, etc.), waste materials containing
chemotherapy drug residues, open containers of drugs that cannot be used,
containers that held substances regulated under the federal Resource
Conservation and Recovery Act, drugs that are discarded, and contaminated
garments, absorbents and spill cleanup material. WISC. DEP'T OF NAT. RES.,
EVALUATING & MANAGING PHARMACEUTICAL WASTE, HEALTH CARE INITIATIVE
FACT SHEET (2008), available at http://dnr.wi.gov/files/pdf/pubs/wa/wa]25 7.pdf.
An EPA-funded study explained that:
Pharmaceutical waste is not one single waste stream, but many distinct
waste streams that reflect the complexity and diversity of the chemicals
that comprise pharmaceuticals. Pharmaceutical waste is potentially
generated through a wide variety of activities in a healthcare facility,
including but not limited to intravenous (IV) preparation, general
compounding, spills/breakage, partially used vials, syringes, and IVs,
discontinued, unused preparations, unused unit dose repacks, patients'
personal medications and outdated pharmaceuticals.
CHARLOTTE SMITH, MANAGING PHARMACEUTICAL WASTE: A 10-STEP
BLUEPRINT FOR HEALTHCARE FACILITIES IN THE UNITED STATES 8 (2008).
10 See infra notes 65-163 and accompanying text.
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targets pharmaceuticals once they reach the waste stream.
1. THE THREATS POSED BY PHARMACEUTICALS IN THE
ENVIRONMENT
A. Background to the Threat
Pharmaceutical pollutants are found in nearly every comer of
the globe, in rivers and lakes, ground water resources, and soils. "
A U.S. Geological Survey study conducted in 1999-2000 sampled
139 streams throughout the United States and found at least one of
ninety-five organic wastewater contaminants, such as "antibiotics,
other prescription drugs, nonprescription drugs, steroids, [and]
reproductive hormones," in 80 percent of stream samples. 12 In
2008, an investigation by the Associated Press revealed "[a] vast
array of pharmaceuticals including antibiotics, anti-convulsants,
mood stabilizers and sex hormones ... in the drinking water
supplies of at least 41 million Americans" in twenty-four major
metropolitan communities.13 More recently, a 2013 study funded
by the U.S. Environmental Protection Agency (EPA) sampled fifty
large wastewater treatment plants nationwide and discovered at
least twenty-five different active pharmaceutical ingredients in the
waste stream, including pain-relief medicines like oxycodone,
blood thinners like warfarin, high blood pressure medication and
beta blockers like hydrochlorothiazide, atenolol and metoprolol,
and over-the-counter drugs like Tylenol and ibuprofen. 14
11 See Christian G. Daughton, PPCPs in the Environment: Future
Research-Beginning with the End Always in Mind, in PHARMACEUTICALS IN
THE ENVIRONMENT: SOURCES, FATE, EFFECTS AND RISKS 463, 463 (Klaus
Ktimmerer ed., 2d ed. 2004); Eckstein & Sherk, supra note 5, at 372. While
pharmaceuticals have been detected in the environment since the 1970s,
attention to these "emerging pollutants" became more pronounced in the 1990s
when newer, more sensitive technologies for detecting and analyzing these
pollutants were developed. Today, scientists have tools that allow them to
identify micropollutants in all waters and soils at levels less than a nanogram
(one billionth of a gram) per liter. See HUMAN PHARMACEUTICALS, HORMONES
AND FRAGRANCES 2-3 (Thomas A. Temes & Adriano Joss eds., 2006).
12 Dana W. Kolpin et al., Pharmaceuticals, Hormones, and Other Organic
Wastewater Contaminants in U.S. Streams, 1999-2000: A National
Reconnaissance, 35 ENVTL. SCI. & TECH. 1202, 1203 (2002).
13 Donn, supra note 8.
14 M.S. Kostich et al., Concentrations of Prioritized Pharmaceuticals in
Effluents from 50 Large Wastewater Treatment Plants in the U.S. and
Implications for Risk Estimation, 184 ENVTL. POLLUTION 354 (2014) (identifying
in the waste stream pain relief medicines like oxycodone, blood thinners like
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While some pharmaceutical components are naturally
occurring, the most significant sources of pharmaceuticals in the
environment are anthropogenic. 15 Pharmaceuticals reach the
environment in many ways, including through waste from
hospitals, health clinics, doctor offices, and nursing homes;' 6
pharmacies; 17 discarded products and wastes from pharmaceutical
manufacturers and distributors;' 8 wastes from veterinary health
care, aquaculture, and animal husbandry activities;19 and the
inappropriate disposal of unwanted medications (e.g., flushed
warfarin, high blood pressure medication and beta blockers like
hydrochlorothiazide, atenolol and metoprolol, and over-the-counter drugs like
Tylenol and ibuprofen).
15 See ED MEANS ET AL., ENDOCRINE DISRUPTORS AND PHARMACEUTICALS
STRATEGIC INITIATIVE EXPERT WORKSHOP REPORT 5 (2007) (stating, with regard
to endocrine disrupting chemicals, that, "[w]hile some estrogenic compounds
occur naturally, most of the detected estrogenic compounds are introduced from
man-made sources").
16 See Temes & Joss, supra note 11, at 25. One of the more conspicuously
wasteful practices is the disposal of excess drugs in hospitals and clinics.
Manufacturers typically produce pharmaceutical products in only a few specific
sizes and doses. As a result, doctors and nurses are challenged by matching these
products sizes and dozes to their patients, who often require only partial dosages
of specific medications. Drug use regulations require unused portions to be
discarded. These portions usually end up in sinks or toilets. See e.g., Erin Jordan,
Dealing with Drug Waste in the Corridor, GAZEtTE (Feb. 2, 2014), available
at http://thegazette.com/2014/02/02/dealing-with-drug-waste-in-the-corridor/
(describing findings at a hospital in Iowa City, Iowa, where, in fiscal year 2013,
hospital staff discarded 47,000 I-millimeter hydromorphone syringes that
contained an average of 0.7 millimeters of the drug, and findings from an
Albany, New York hospital where staff regularly discarded 90 percent of
propofol, a common anesthetic, because the containers were oversized and
regulations required disposal of unused portions).
17 See, e.g, Mike Lee, CVS Agrees To Pay Big Fine in Dumping Case, SAN
DIEGO UNION TRIB. (Apr. 18, 2012, 2:49 PM), http://www.utsandiego.com/
news/2012/apr/1 8/cvs-agrees-pay-big-fine-dumping-case/.
18 See e.g., Patrick J. Phillips et al., Pharmaceutical Formulation Facilities
as Sources of Opioids and Other Pharmaceuticals to Wastewater Treatment
Plant Effluents, 44 ENVTL. SCI. & TECH. 4910 (2010); Manufacturing Facilities
Release Pharmaceuticals to the Environment, U.S. GEOLOGICAL SURVEY (May
20, 2010), http://toxics.usgs.gov/highlights/PMFs.html; Jeff Donn, et al., US
Water Contaminated By Pharmaceutical Companies, Hospitals, Consumers,
HUFFINGTON POST (Apr. 20, 2009), http://www.huffingtonpost.com/2009/04/20/
us-water-contaminated-by-_n_188852.html (asserting that "U.S. manufacturers,
including major drugmakers, have legally released at least 271 million pounds of
pharmaceuticals into waterways that often provide drinking water").
19 Klaus Kimmerer, Pharmaceuticals in the Environment-Scope of the
Book and Introduction, in PHARMACEUTICALS IN THE ENVIRONMENT: SOURCES,
FATE, EFFECTS AND RISKS 3, 5 (Klaus Kammerer ed., 2d ed. 2004).
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down toilets). 20 Other sources of pharmaceutical pollution that are
less obvious include human and animal feces and urine,21 coroner
office wastes, 22 bath water, 23 leachate from landfills containing
improperly discarded pharmaceutical products and items
contaminated with pharmaceutical residues, 24 and irrigation water
sourced from reclaimed wastewater. 25 While human excretion is
20 Paul D. Anderson et al., Screening Analysis of Human Pharmaceutical
Compounds in U.S. Surface Waters, 38 ENVTL. Sci. & TECH. 838, 838 (2004);
J.B. Ellis, Pharmaceutical and Personal Care Products (PPCPs) in Urban
Receiving Waters, 144 ENVTL. POLLUTION 184, 185 (2006). In California, a 2007
unused medication collection program suggests that 52 percent of over-the-
counter drugs and 45 percent of prescription medicines are discarded unused.
TELEOSIS INST., GREEN PHARMACY PROGRAM: HELPING COMMUNITIES SAFELY
DISPOSE OF UNUSED MEDICINES (2007), available at http://www.teleosis.org/pdf/
GreenPharmacy FullPreliminaryReport.pdf. A survey from the mid-1990s
reported that only two percent of respondents fully completed their prescription
medication. See Susan T. Glassmeyer et al., Disposal Practices for Unwanted
Residential Medications in the United States, 35 ENV'T INT'L 566, 568 (2009)
(citing to a survey reported in D.S. Kuspis & E.P. Krenzelok, What Happens to
Medications? A Survey of Community Medication Disposal, 38 VETERINARY
HUM. TOXICOLOGY 48-49 (1996)).
21 For example, a recent study reported that 90 percent of the active
ingredients of the beta blocker Atenolol and 60 percent of the antibiotic
Amoxycillin remain unmetabolized as they move through the human body and,
thereafter, are excreted. See CHRIS WATTS ET AL., DESK BASED REVIEW OF
CURRENT KNOWLEDGE ON PHARMACEUTICALS IN DRINKING WATER AND
ESTIMATION OF POTENTIAL LEVELS 32 (2007). Excretion rates for antibiotics
used in animal health care are estimated at between 25 and 75 percent. MAE WU
ET AL., DOSED WITHOUT PRESCRIPTION: PREVENTING PHARMACEUTICAL
CONTAMINATION OF OUR NATION'S DRINKING WATER 32 (2009).
22 Ilene S. Ruhoy & Christian G. Daughton, Types and Quantities of
Leftover Drugs Entering the Environment via Disposal to Sewage-Revealed by
Coroner Records, 388 ScI. TOTAL ENV'T 137, 144-145 (2007) (revealing that
during the 13-month study period: of the pharmaceuticals collected at crime
scenes and taken to coroner' offices, 92 percent were flushed and eight percent
discarded in the trash; 325,000 pharmaceuticals were disposed of in the sewage
system amounting to 102 kilograms of pharmaceutical wastes; extrapolating
these figures nationally suggests that approximately 17.9 metric tons of
pharmaceutical waste is disposed of annually by coroners in municipal sewage
systems).
23 Christian G. Daughton & Ilene S. Ruhoy, Environmental Footprints of
Pharmaceuticals: The Significance of Factors Beyond Direct Excretion to
Sewers, 28 ENVTL. TOXICOLOGY & CHEMISTRY 2495, 2495 (2009); Erin M.
Snyder et al., Pharmaceuticals and EDCS in the U.S. Water Industry-An
Update, 97 J. AM. WATER WORKS ASS'N 32 (2005).
24 Mark J. Benotti et al., Pharmaceuticals and Endocrine Disrupting
Compounds in U.S. Drinking Water, 43 ENVTL. Sci. & TECH. 597 (2009);
Reynolds, supra note 6.
25 See WUETAL.,supra note 21, at3.
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thought to be the chief source of active pharmaceutical ingredients
in the environment,26 the relative contribution of each of the
sources to environmental loadings is still uncertain due to a lack of
precise data on the use rates, disposal practices, and disposal
routes of various pharmaceutical substances.2 7 Figure 1 depicts
how pharmaceutical pollutants generally enter the environment
and drinking water supplies.
Figure 1: Chief pathways for pharmaceuticals to enter the
environment and drinking water supplies
Sewage tandfill Disposal
Drinking Water --
The presence of these drugs in the environment should not
come as a surprise. In 2012, Americans spent $325 billion on
prescription medicines. 28 A 2008 study indicates that between
1998 and 2008, the percentage of Americans taking at least one
prescribed medication monthly increased from 44 to 48 percent. 29
26 See Klaus Kiimmerer, Strategies for Reducing the Input of
Pharmaceuticals Into the Environment, in PHARMACEUTICALS IN THE
ENVIRONMENT: SOURCES, FATE, EFFECTS AND RISK 416 (Klaus Kfimmerer ed.,
2008).
27 Alexandra Titz & Petra D611, Actor Modelling and Its Contribution to the
Development of Integrative Strategies for Management of Pharmaceuticals in
Drinking Water, 68 SOC. SC. & MED. 672, 673 (2009).
28 Katie Thomas, U.S. Drug Costs Dropped in 2012, but Rises Loom,
N.Y. TIMES, Mar. 18, 2013, http://www.nytimes.com/2013/03/19/business/use-
of-generics-produces-an-unusual-drop-in-drug-spending.html?pagewanted=all
(reporting that while 2012 saw a slight drop in prescription drug sales in the
United States, the market is expected to rise by four percent in 2014 and
continue to rise in the near future).
29 QIUPING GU ET AL., U.S. DEP'T OF HEALTH & HUMAN SERVS., NCHS
DATA BRIEF NO. 42, PRESCRIPTION DRUG USE CONTINUES TO INCREASE: U.S.
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In 2013, the average American filled 12.3 prescriptions annually at
retail pharmacies, 30  amounting to nearly four billion
prescriptions. 31 Moreover, most pharmaceuticals are designed to
be persistent so as to reach the body part targeted for
pharmacological benefit.32 That persistence translates into a
resistance to natural degradation in the environment.
33
Despite the known prevalence and persistence of these
contaminants in the environment, most wastewater and freshwater
installations and processes rarely target these contaminants for
treatment or removal.34 In fact, the vast majority of treatment
operations do not have the capacity, resources, or technology
necessary to remove pharmaceuticals pollutants from the waste
stream or freshwater supply sources. 35 Moreover, "given the vast
PRESCRIPTION DRUG DATA FOR 2007-2008, at 1 (2010), available at http:/www.
cdc.gov/nchs/data/databriefs/db42.pdf. The study further noted that, during the
same study period, the percentage of Americans taking at least two prescribed
medication monthly increased from 25 to 31 percent, and the use of five or more
drugs increased from 6 to 11 percent. Id. The most commonly used types of
drugs included: asthma medicines for children, central nervous system stimulants
for adolescents, antidepressants for middle-aged adults, and cholesterol-lowering
drugs for older Americans. Id. at 1, 5.
30 State Health Facts: Retail Prescription Drugs Filled at Pharmacies
(Annual per Capita), HENRY J. KAISER FAMILY FOUND., http://kff.org/other/
state-indicator/retail-rx-drugs-per-capita/#table (last visited Sept. 16, 2014).
31 State Health Facts: Total Number of Retail Prescription Drugs Filled at
Pharmacies, HENRY J. KAISER FAMILY FOUND., http://kff.org/other/state-
indicator/total-retail-rx-drugs/ (last visited Sept. 16, 2014).
32 See Ternes & Joss, supra note 11, at 386.
33 See Staffan Castensson, Pharmaceutical Waste, in PHARMACEUTICALS IN
THE ENVIRONMENT: SOURCES, FATE, EFFECTS AND RISK 489, 497 (Klaus
Ktimmerer ed., 2008) ("Pharmaceuticals are designed to be resistant to biological
degredation"); cf Daughton & Temes, supra note 2, at 907, 933 (noting "that
many of these compounds survive biodegradation" but also explaining that
"[p]ersistence is not critical if the source is constant, leading to perpetual aquatic
exposure").
34 Cf Castensson, supra note 33, at 497 (noting that treatment facilities for
wastewater "are designed to remove conventional pollutants.., but they are not
designed to remove low concentrations of synthetic pollutants such as
pharmaceuticals").
35 Suzanne Avena & Dayna Tann, The Hazards of Pharmaceutical
Disposal: Arising Issues of Concern, 23 WESTLAW J. ENVTL. 1, 3 (2013)
(asserting that "traditional wastewater treatment is not designed to remove
pharmaceuticals" and that "while some of the upgraded facilities have more
advanced treatment technologies, even these facilities are not specifically
designed to remove pharmaceuticals. As a result, significant amounts of
pharmaceutical waste pass through without being filtered, resulting in the waste
ultimately passing into our waterways"); Shawna Bligh, Pharmaceuticals in
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array of mechanisms of drug action and side effects, the total
number of different toxicity tests possibly required to screen the
effluent from a typical [sewage treatment plant] could be
impractically large." 36 As a result, pharmaceutical pollutants
persist in waters discharged from wastewater treatment plants into
receiving streams and lakes, 37 solid and liquid wastes applied to
designated land application sites, 38 and municipal water supplies. 39
While numerous studies identifying pharmaceutical pollutants
in the nation's freshwater resources emphasize that these
substances are predominantly found at subtherapeutic levels 4
0
(typically measured in quantities of parts per billion or trillion), the
vast majority acknowledge a causal relationship with
abnormalities and other health impacts to various aquatic
species. 41 Few negate the possibility of ill effects on people. 42
B. Human Exposure to Pharmaceuticals
The most obvious pathway for unintentional human exposure
to pharmaceutical substances or pollutants is ingesting
Surface Waters: Use of NEPA, NAT. RES. & ENV'T, Fall 2009, at 56, 56
(indicating that "the efficiency of wastewater treatment processes to eliminate
active drug compounds may be as low as 7 percent").
36 Daughton & Ternes, supra note 2, at 923.
37 Juliane B. Brown et al., Lagrangian Sampling for Emerging
Contaminants Through an Urban Stream Corridor in Colorado, 45 J. AM.
WATER RES. Ass'N 68, 69-70 (2009) (asserting that treated wastewater
frequently contains "antioxidants . . . pharmaceuticals [prescription and
nonprescription drugs] ... and steroidal compounds... "). Such wastewater
"has been shown to contain low, yet biologically active, concentrations of
estrogenic compounds." Mario K. Sellin et al., Estrogenic Compounds
Downstream from Three Small Cities in Eastern Nebraska: Occurrence and
Biological Effect, 45 J. AM. WATER RES. ASS'N 14, 15 (2009).
38 Sarah C. Monteiro & Alistair B.A. Boxall, Pharmaceuticals and Personal
Care Products in the Environment: Factors Affecting the Degradation of
Pharmaceuticals in Agricultural Soils, 28 ENVTL. TOXICOLOGY & CHEMISTRY
2546 (2009) (noting that "[i]n biosolids destined for land application, a number
of pharmaceuticals.., have been detected").
39 See Harvey, supra note 8; Jeffrey Kluger, PHARMA in the Plumbing:
Flushed Away, TIME (Apr. 1, 2010), http://content.time.com/time/specials/
packages/article/0,28804,1976909_1976907_1976871,00.html; Donn, supra
note 8.
40 Subtherapeutic definition, DICTIONARY.COM, http://dictionary.
reference.com/browse/subtherapeutic(last visited July 26, 2015) ("indicating a
dosage, as of a drug or vitamin, less than the amount required for a therapeutic
effect").
41 See infra notes 53-61 and accompanying text:
42 See infra notes 43-52 and accompanying text.
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contaminated water. Exposure may also occur through the
consumption of fish and shellfish that have bioaccumulated
pharmaceuticals or through contact with contaminated water. 43 In
reality, there is seldom a single exposure pathway. The National
Research Council notes the existence of both "major and minor
exposure pathways" and concludes that future risk assessments for
pharmaceutical aggregate exposure should be evaluated across
multiple pathways. 44 The Council further recommends, "where the
same receptor is likely to be exposed to more than one pathway,
exposures should be added across pathways. '45
Evidence of harm from human exposure to pharmaceutical
pollutants is inconclusive. Studies suggest that short-term
exposure to low levels of specific pharmaceutical pollutants does
not result in adverse human health impacts. 46 However, studies
describing short-term exposure to high levels of specific
pharmaceuticals are lacking. Moreover, studies of long-term or
chronic human exposure to these substances suggest possible
43 Virginia L. Cunningham et al., Human Health Risk Assessment from the
Presence of Human Pharmaceuticals in the Aquatic Environment, 53
REGULATORY TOXICOLOGY & PHARMACOLOGY 39, 43 (2009); Ellis, supra note
20, at 185; Ake Wennmalm & Bo Gunnarsson, Public Health Care Management
of Water Pollution with Pharmaceuticals: Environmental Classification and
Analysis of Pharmaceutical Residues in Sewage Water, 39 DRUG INFO. J. 291,
296 (2005).
44 COMM. ON TOXICANTS & PATHOGENS IN BIOSOLIDS APPLIED TO LAND,
NAT'L RESEARCH COUNCIL, BIOSOLIDS APPLIED TO LAND: ADVANCING
STANDARDS AND PRACTICES 240-41 (2002), available at http://www.nap.edu/
openbook.php?record id= 10426&page=240.
45 Id.; see also Kolpin et al., supra note 12, at 1202 (asserting that "there are
a wide variety of transport pathways for many different chemicals to enter and
persist in environmental waters").
46 See e.g., WORLD HEALTH ORG., supra note 8, at 14 (asserting that
"discernible risks to health arising from trace levels of pharmaceuticals in
drinking-water are extremely unlikely"); GLOBAL WATER RESEARCH COALITION,
OCCURRENCE AND POTENTIAL FOR HUMAN HEALTH IMPACTS OF
PHARMACEUTICALS IN THE WATER SYSTEM 2 (2009), available at
http://wvvw.weftec.org/WorkArea/DownloadAsset.aspx?id=3910 (stating that,
"to date, no definitive link has been reported or established between
pharmaceutical exposure in drinking water and human health risk"); GEORGE
WASHINGTON SCH. OF PUB. HEALTH & HEALTH SERVS. RAPID PUB. HEALTH
POLICY RESPONSE PROJECT, PHARMACEUTICALS ARE IN THE DRINKING WATER:
WHAT DOES IT MEAN? 1 (2008),("At current levels, pharmaceutical residues are
unlikely to pose an immediate risk to human health, but the long-term
consequences of individual chemicals, and combinations of chemicals, are
unknown, especially as concentrations rise.").
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harmful impacts to human health.47 For example, one researcher
observed that "[t]rends of increased testicular cancer, reproductive
abnormalities, breast cancer, early puberty and decreased sperm
count have all been suggested as problems possibly related to low-
level exposure to chemicals (pharmaceuticals and endocrine
disrupting compounds (EDCs)) in the environment. 48
Human exposure to pharmaceuticals, however, is rarely
isolated to one specific drug or medicinal component. Exposure
typically occurs to combinations of substances, the impacts of
which are also relatively unknown. 49  Combinations of
pharmaceuticals are believed to have cumulative or synergistic
effects that go beyond the effects of any single pharmaceutical. 50
Moreover, studies indicate that in addition to cumulative or
synergistic effects, certain pharmaceuticals may become more
persistent when combined. 51 Unfortunately, "it is not clear what
toxicological implications chronic exposure to suites of trace
contaminants may pose." 52
47 See e.g., Gerd Hamscher & Jorg Hartung, Veterinary Antibiotics in Dust:
Sources, Environmental Concentrations, and Possible Health Hazards, in
PHARMACEUTICALS IN THE ENVIRONMENT: SOURCES, FATE, EFFECTS AND RISK 95
(Klaus Kiimmerer ed., 2008); Sungpyo Kima & Diana S. Aga, Potential
Ecological and Human Health Impacts of Antibiotics and Antibiotic-Resistant
Bacteria from Wastewater Treatment Plants, 10 J. TOXICOLOGY & ENVTL.
HEALTH, PART B: CRITICAL REVIEWS 559 (2007); Oliver A. Jones, et al.,
Pharmaceuticals: A Threat to Drinking Water?, 23 TRENDS IN BIOTECHNOLOGY
163 (2005); Reynolds, supra note 6.
48 Reynolds, supra note 6, at 2. EDCs are chemical substances that at certain
doses can interfere with human (and other mammals') endocrine or hormone
systems. See What Are Endocrine Disruptors?, U.S. ENVTL. PROT. AGENCY,
http://www.epa.gov/endo/pubs/edspoverview/whatare.htm (last updated Aug. 11,
2011).
49 Helen C. Poynton & Chris D. Vulpe, Ecotoxicogenomics: Emerging
Technologies for Emerging Contaminants, 45 J. AM. WATER RES. ASS'N 83, 91
(2009) (stating that "[i]n field situations, organisms are exposed to not just one
compound but a m~lange of contaminants, which can interact within the
environment and individual organisms").
50 Kolpin et al., supra note 12, at 1210.
51 Monteiro, supra note 38, at 2553 ("As pharmaceuticals will never be in
the environment as single compounds, a consideration of the impacts of mixtures
of different pharmaceuticals and pharmaceuticals and other compounds needs to
be assessed. Our preliminary data demonstrate that degradation may be
significantly slower in mixtures.").
52 Benotti, supra note 24, at 597; cf GEORGE WASHINGTON SCH. OF PUB.
HEALTH & HEALTH SERVS, supra note 46, at 4 (adding that "[a] limited body of
research... suggests an additive effect when a mixture of pharmaceuticals is
present").
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C. Environmental Impacts from Pharmaceuticals
In contrast to human exposure, many aquatic species are
continuously subjected, over multiple generations, to
pharmaceuticals in their natural habitats. 53 As a result, studies on
the health impacts of pharmaceutical exposure are more
conclusive. For example, the low-level presence of pharmaceutical
estrogens has led to "a suite of adverse effects" for certain fish and
other aquatic vertebrates, including the feminization of males,54
impaired reproductive capacity,55  and abnormal sexual
development. 56 In contrast, exposure to trebolone metabolites
found in steroids used to promote muscle growth is known to
cause masculinization and lower fertility rates in female fish. 57
Moreover, antidepressants are believed to "trigger premature
spawning in shellfish while drugs designed to treat heart ailments
block the ability of fish to repair damaged fins." 5 Focusing on
endocrine disrupting compounds, one researcher concluded:
[These] are compounds that interfere with natural production,
release, transport, metabolism, binding, action, or elimination of
hormones in the body.... Small disturbances in endocrine
function, especially during certain stages of the life cycle, can
lead to profound and lasting effects. There is evidence that
53 GEORGE WASHINGTON SCH. OF PUB. HEALTH & HEALTH SERVS, supra
note 46, at 4. Aquatic species, however, are not the only species detrimentally
affected by the presence of pharmaceuticals in the environment. See e.g., Rhys
Green et al., Collapse of Asian Vulture Populations: Risk of Mortality from
Residues of the Veterinary Drug Diclofenac in Carcasses of Treated Cattle, 43 J.
APPLIED ECOLOGY 949 (2006); Susanne Shultz, et al., Diclofenac Poisoning is
Widespread in Declining Vulture Populations Across the Indian Subcontinent,
271 PROC. ROYAL SOC'Y LONDON S458, S458 (2004) (both studies discussing
unmistaken causal relationship between use of the veterinary drug diclofenac, a
non-steroidal anti-inflammatory drug used to treat farm animals, and the death of
95 percent of India's and 90 percent of Pakistan's Gyps vulture populations).
54 Sellin, supra note 37, at 14; Natasha Gilbert, Drug Waste Harms Fish,
476 NATURE 265, 265 (2011); Karen A. Kidd et al., Collapse of a Fish
Population After Exposure to a Synthetic Estrogen, 104 PROC. NAT'L ACAD. SCI.
8897, 8897 (2007).
55 Sellin, supra note 37, at 14-15; see also Poynton & Vulpe, supra note 49,
at 84; Heiko L. Schoenfuss et al., Effects of Exposure to Low Levels of Water-
Borne 17fi-Estradiol on Nest Holding Ability and Sperm Quality in Fathead
Minnows, 120 WATER RES. UPDATE 49 (2001).
56 Sellin, supra note 37, at 15; Gilbert, supra note 54, at 265.
57 See E.J. Durhan et al. Identification of Metabolites of Trenbolone Acetate
in Androgenic Runoff from a Beef Feedlot, 114 ENVTL. HEALTH PERSP. 65, 67
(2006).
58 Reynolds, supra note 6.
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specific populations of invertebrate, fish, avian, reptilian, and
mammalian species have been, or currently are being, adversely
affected by exposure to environmental contaminants that effect
the endocrine systems .... 59
The presence of pharmaceutical pollutants in the environment
potentially affects organisms throughout the food web. However,
since the majority of organisms studied for possible
pharmaceutical impacts are at the bottom of the food chain, the
consequences that these organisms may have on species higher in
the chain is generally unknown. 60 Nevertheless, the fact that
chronic exposure to pharmaceuticals has been found to negatively
impact the health of the base food-chain species suggests a
likelihood of similar consequences for those higher in the chain.6'
D. Gaps in Knowledge
Current knowledge about the impact of pharmaceuticals on
people and ecosystems is inadequate to provide a clear
understanding of the sources of these pollutants and all the
potential implications of exposure. In particular, more information
is needed about the various pathways that pharmaceutical
pollutants take to reach the environment and, especially, their
relative contribution to the presence of these environmental
contaminants. 62 In addition, there is a dearth of information on the
effects of long-term, low-dose human exposure to the multitude of
pharmaceutical pollutants.63 Similarly, research is needed on the
synergistic effects and health impacts that exposure to multiple
59 Robert W. Masters, Pharmaceuticals and Endocrine Disruptors in Rivers
and on Tap, 120 WATER RESOURCES UPDATE 1 (2001).
60 Talia E. A. Chalew & Rolf U. Halden, Environmental Exposure of
Aquatic and Terrestrial Biota to Triclosan and Triclocarban, 45 J. AM. WATER
RES. Ass'N 4, 10 (2009). One of the only pharmaceutical impact studies of a
species high in the food chain was conducted on Pakistan's Gyps vultures,
whose population was decimated as a result of consuming farm animals treated
with the non-steroidal anti-inflammatory drug diclofenac. See supra note 53.
61 See Chalew & Halden, supra note 60, at 10; Poynton & Vulpe, supra note
49, at 84.
62 See Daughton, Pharmaceuticals in the Environment, supra note 2, at 54
(discussing lack of information, including source contribution and environmental
loading); see also supra notes 15-27 and accompanying text.
63 "Although a wealth of toxicological information may be available for
pharmaceuticals, the effects of unintended chronic exposure to subtherapeutic
doses that could occur via consumption of drinking water are often not known."
Snyder, supra note 23, at 33.
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pharmaceutical substances and waste may pose to humans and
other species. 64  Without this information, regulatory and
management schemes will not be fully effective or protect the
human and natural environments as intended.
II. THE FEDERAL APPROACH TO MANAGING PHARMACEUTICALS IN
THE ENVIRONMENT
The U.S. Congress has not yet adopted legislation specifically
aimed at managing pharmaceutical pollutants in the environment.
A number of federal agencies have interpreted three environmental
statutes-the Resource Conservation and Recovery Act (RCRA), 65
the Clean Water Act (CWA), 6 6 and the Safe Drinking Water Act
(SDWA) 67-as applicable to certain pharmaceutical wastes in the
waste stream, and another-the National Environmental Policy
Act (NEPA)68-to the manufacturing of drug products in relation
to their potential to reach the natural environment. However, none
of these statutes were specifically designed with pharmaceuticals
in mind, and they have proven inadequate to resolve the challenges
posed by pharmaceutical pollutants in the environment.
A. Resource Conservation and Recovery Act
RCRA is a federal program for the "cradle-to-grave"
management of hazardous substances and waste.69 One of the
statute's express goals is to protect human health and the
environment from the hazards posed by waste disposal. 70 Other
goals include the reduction or elimination of the amount of waste
generated (including hazardous waste), and the proper
management of such waste to protect human health and the
environment. 7 |
64 See supra notes 49-52 and accompanying text.
65 Resource Conservation and Recovery Act (RCRA) of 1976, 42 U.S.C. §§
6901-6992k(2012).
66 Clean Water Act (CWA), 33 U.S.C. §§ 1251-1387 (2012).
67 Safe Drinking Water Act (SWDA), 42 U.S.C. § 300f-300j-26 (2012).
68 National Environmental Policy Act (NEPA), 42 U.S.C. § 4321 (2012).
69 David R. Case, Resource Conservation and Recovery Act, in 21 ENVTL.
LAW HANDBOOK 141, 142 (Thomas F.P. Sullivan ed., 21st ed. 2011).
70 42 U.S.C. § 6902(a) (providing that "[t]he objectives of this chapter are to
promote the protection of health and the environment and to conserve valuable
material and energy resources... .
71 Id.
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Under RCRA, the EPA, as well as EPA-authorized state
agencies, regulates the generation, storage, transportation,
treatment, and disposal of hazardous solid wastes. 72 EPA identifies
wastes as "hazardous" based on any one or a combination of four
characteristics: ignitable, corrosive, toxic, or reactive. 73
RCRA specifically excludes certain wastes from its scope,
even when those wastes may otherwise exhibit one of the above
72 Under RCRA, 42 U.S.C. § 6903(5), "hazardous" waste includes:
[A]ny solid waste, or combination of solid wastes, which because of its
quantity, concentration, or physical, chemical, or infectious
characteristics may (A) cause, or significantly contribute to an increase
in mortality or an increase in serious irreversible, or incapacitating
reversible illness; or (B) pose a substantial present or potential hazard
to human health or the environment when improperly treated, stored,
transported, or disposed of, or otherwise managed.
RCRA, 42 U.S.C. § 6903(27), defines "solid waste" as:
[A]ny garbage, refuse, sludge from a waste treatment plant, water
supply treatment plant or air pollution control facility and other
discarded material, including solid, liquid, semisolid, or contained
gaseous materials resulting from industrial, commercial, mining and
agriculture activities and from community activities but does not
include solid or dissolved material in domestic sewage, or solid or
dissolved materials in irrigation return flows or industrial discharges
which are point sources subject to permits under section 402 of the
Federal Water Pollution Control Act, as amended, or source, special
nuclear, or byproduct material as defined by the Atomic Energy Act of
1954, as amended (68 Stat. 923).
73 See 40 C.F.R. § 261.20-261.24 (2014); Characteristic Wastes, U.S.
ENVTL. PROT. AGENCY, http://www.epa.gov/osw/hazard/wastetypes/
characteristic.htm (last updated May 8, 2013). EPA also classifies wastes as
hazardous, in two groups, in relation to their potential effect on humans or
animals. The first group includes those substances that are acutely toxic and can
be fatal to humans or animals above certain minimum thresholds or doses. The
second group encompasses substances that either exhibit any of the four
hazardous characteristics noted above or contain a toxic constituent (e.g.,
chemical compounds or elements that have been shown to have toxic,
carcinogenic, mutagenic, or teratogenic effects on humans or other life forms)
capable of posing a "substantial present or potential hazard to human health or
the environment when improperly treated, stored, transported, or disposed of, or
otherwise managed." 42 U.S.C. § 6903(5). While the former are listed in
RCRA's so-called P-list, the latter are found in RCRA's U-list. RCRA's P-list
contains 239 different "acutely toxic" substances of which 15 have been
identified by the Healthca're Environmental Resources Center (HERC) as likely
to be found in a healthcare facility (e.g., arsenic, cyanide salt, nitroglycerin, and
Strychnine). Hazardous Waste Determination, HEALTHCARE ENVTL. RES. CTR.,
http://www.hercenter.org/hazmat/hazdeterm.cfm (last visited Mar. 23, 2014).
RCRA's U-list contains 472 distinct substances of which 66 have been identified
by the HERC as likely to be found in a healthcare, facility (e.g., acetone,
chloroform, ethyl ether, and Warfarin). Id.
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characteristics or fall within one of the above classifications. In
particular, RCRA excludes domestic sewage, "[a]ny mixture of
domestic sewage and other wastes that passes through a sewer
system to a publicly-owned treatment works for treatment," and
"[i]ndustrial wastewater discharges that are point source
discharges subject to regulation under ... the Clean Water Act"
from its requirements. 74 In addition, RCRA applies only to those
facilities that generate, store, transport, or dispose of more than
one hundred kilograms of hazardous waste per month or any
amount of acute hazardous waste per month.75
Accordingly, while drugs and drug residues in household
municipal wastes are excluded from RCRA's program, the statute
applies to the thousands of health care facilities-including
hospitals, clinics, and nursing homes, and pharmaceutical
manufacturers and dispensers, throughout the United States-that
generate, store, transport, or dispose of more than one hundred
kilograms of hazardous pharmaceutical waste per month or any
amount of acute hazardous pharmaceutical waste per month. 76 The
statute likewise applies to doctor and veterinarian offices.77 Yet, in
2005, only ninety-four hospitals and nineteen pharmacies became
subject to any of RCRA's generation, storage, transportation,
treatment, disposal, or reporting criteria. 78 Given that in that same
year, there were more than 7,000 hospitals, 72,000 nursing homes
and related long-term-care facilities, 27,000 veterinary care
operations, 40,000 retail pharmacies, and 300,000 physician and
dental offices in the United States, 79 it is inconceivable that only
slightly more than one percent of hospitals, fewer than 0.05
percent of pharmacies, and no long-term care or veterinary care
74 40 C.F.R. § 261.4(a)(1)-(2) (2014).
75 40 C.F.R. § 261.5(a) (2014). Waste is defined as "acute hazardous waste"
if it is capable of causing or significantly contributing to an increase in serious
irreversible, or incapacitating reversible, illness. 40 C.F.R. § 261.11 (a)(2) (2014).
76 RCRA applies to any entity that generates, stores, transports, or disposes
of at least 100 kilograms of hazardous waste per month or any amount of acute
hazardous waste per month, including certain pharmaceutical wastes. Cf supra
notes 72, 75 and accompanying text.
77 Doctor and veterinarian offices are exempt only if they generate no more
than one hundred kilograms of hazardous waste per month. 40 C.F.R. § 261.5(a)
(2014).
78 See Amendment to the Universal Waste Rule: Addition of
Pharmaceuticals, 73 Fed. Reg. 73,520, 73,526 (Dec. 2, 2008).
79 Id. at 73,522, 73,526.
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facilities exceeded the minimum RCRA threshold. 80
One of RCRA's chief shortcomings is that it is difficult to
implement and enforce. The regulations depend on self-
reporting,81 and EPA does not have the resources to ensure
compliance throughout the community.82 Moreover, there is a
disconnect between EPA's interpretation and application of the
statute, and the RCRA knowledge held by pharmaceutical and
health care facilities and their staff.83 As a result, many health care
facilities and professionals are entirely unaware whether and how
RCRA applies to their pharmaceutical management and disposal
practices. 84
80 EPA has asserted that all of these hospitals, nursing homes, long-term-
care facilities, veterinary care operations, retail pharmacies, and physician and
dental offices "are likely to generate some volume of pharmaceutical wastes and
many of which will generate some that are RCRA hazardous." See id. at 73,526.
81 Cf id. at 73,527 (explaining that the process of applying RCRA begins
with a generator determining whether a pharmaceutical waste is subject to
RCRA's reporting requirements).
82 The issue of inadequate EPA funding is a recurring theme. See e.g., U.S.
Gov. ACCOUNTABILITY OFFICE, REPORT No. GAO-07-883, ENVIRONMENTAL
PROTECTION: EPA-STATE ENFORCEMENT PARTNERSHIP HAS IMPROVED, BUT
EPA's OVERSIGHT NEEDS FURTHER ENHANCEMENT (2007), available at
http://www.gao.gov/assets/270/264845.pdf; Coral Davenport, EPA Funding
Reductions Have Kneecapped Environmental Enforcement, NAT'L J. (May
4, 2013), http://www.nationaljournal.com/daily/epa-funding-reductions-have-
kneecapped-environmental-enforcement-20130303.
83 See Wu ET AL., supra note 21, at 31 (noting that "[a] significant barrier to
ensuring responsible disposal of pharmaceuticals is that very few medical
professionals, including doctors, nurses, pharmacists, or administrators,
understand all the issues related to disposal. They are not taught the
consequences of various disposal methods nor do they have any training in
RCRA or other legal requirements that govern disposal of some pharmaceutical
products when generated in large enough quantities"). Cf Ron Seely, Flushed
Drugs Polluting Water: Complicated Rules for Disposal Result in Most
Hospitals Taking Easy Way Out, MADISON.COM (Dec. 10, 2006, 12:00 AM),
http://host.madison.com/news/flushed-drugs-polluting-water-complicated-rules-
for-disposal-result-in/article acdb4a7b-6a05-5c6f-aeae-2e243 1 e515d7.html
(observing that proper drug disposal is a confusing and expensive process for
hospitals and other health-care institutions with little agency oversight or
guidance).
84 As EPA asserts, "numerous health care facilities are either unaware of
how the hazardous waste regulations apply to pharmaceutical wastes or, even if
there is knowledge of RCRA, they have problems with training the workers that
are generating these wastes on how to manage hazardous wastes properly." See
Amendment to the Universal Waste Rule, 73 Fed. Reg. 73,520, 73,527 (Dec. 2,
2008). EPA further states that, "[w]hile the vast majority of pharmaceutical
waste generators are undoubtedly [small quantity generators] ... or
[Conditionally Exempt Small Quantity Generators] .... information provided by
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In addition, given the growing number of pharmaceutical
products and ingredients in society, it is questionable whether EPA
could implement a successful program under RCRA that could
adequately evaluate all of the potential hazards posed by
pharmaceutical pollutants. Currently, there are over 100,000 FDA-
approved human and veterinary (prescription and over-the-
counter) drug products in the United States that contain more than
2,500 structurally unique molecular entities and employ multiple
mechanisms of activity.85 Treating these substances out of the
waste stream would necessitate dozens if not hundreds of disparate
treatment methods and technologies. 86 Yet, the vast majority of
pharmaceuticals-including antibiotics, anti-convulsants,
antidepressants, beta blockers, blood thinners, diuretics, hormones,
steroids, and many others-have yet to be evaluated for their
possible hazardous qualities, let alone mechanisms for their
removal. In fact, EPA has not updated its RCRA pharmaceuticals
list since 1980 when it first listed thirty-one pharmaceutical
substances.8 7 Moreover, EPA has yet to establish a process for
generators themselves show a low level of knowledge about RCRA and its
regulatory requirements, even on the part of some large facilities." Id. at 73,526.
In a scathing rebuke of EPA's regulation of hazardous pharmaceutical wastes,
the USEPA's Office of Inspector General (EPA-OIG) asserted that according to
EPA itself, many "health care workers, retail pharmacy employees, and other
pharmaceutical generators are often unfamiliar with or confused by RCRA
hazardous waste management requirements, prompting them to improperly
dispose of hazardous pharmaceuticals as municipal or bulk wastes." U.S. ENVTL.
PROT. AGENCY, REPORT No. 12-P-0508, EPA INACTION IN IDENTIFYING
HAZARDOUS WASTE PHARMACEUTICALS MAY RESULT IN UNSAFE DISPOSAL 9
(2012), available at http://www.epa.gov/oig/reports/2012/20120525-12-P-
0508.pdf [hereinafter EPA-OIG 2012 REPORT].
85 See Daughton, Pharmaceuticals in the Environment, supra note 2, at 45.
86 See Eckstein & Sherk, supra note 5 at 432-33 (noting that removal of
pharmaceutical wastes from the waste stream requires multiple techniques and
technologies); see also infra note 183 and accompanying text (discussing various
treatment options).
87 See EPA-OIG 2012 REPORT, supra note 84, at 7. According to the
Healthcare Environmental Resources Center, seven of the thirty-one
pharmaceutical substances identified by EPA are found under EPA's P-list
(Arsenic trioxide, Epinephrine, Nicotine, Nitroglycerin, Physostigmine,
Physostigmine salicylate, and Warfarin >0.3 percent), and twenty-four are
included in the Agency's U-list (Chloral Hydrate, Chlorambucil, Chloroform,
Cyclophosphamide, Daunomycin, Dichlorodifluromethane, Diethylstilbestrol,
Formaldehyde, Hexachlorophene, Lindane, Melphalan, Mercury, Mitomycin C,
Paraldehyde, Phenacetin, Phenol, Reserpine, Resorcinol, Saccharin, Selenium
sulfide, Streptozotocin, Trichloromonofluromethane, Uracil mustard, Warfarin
<0.3 percent). Listed Wastes, HEALTHCARE ENVTL. RESOURCE CENTER,
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regularly identifying and reviewing new or existing
pharmaceuticals that may qualify for regulation as RCRA
hazardous waste products."8
In a 2012 report, EPA's Office of Inspector General (EPA-
OIG) asserted that:
RCRA hazardous waste regulations are not keeping up with
drug development and the potential hazards they may pose if
mismanaged and disposed without the necessary protections to
human health and the environment. Without an established
process to review pharmaceuticals, EPA cannot ensure that it
has identified pharmaceutical contaminants that may pose a
hazardous risk to human health and the environment.8 9
In response to the EPA-OIG report, EPA indicated that it
would "consider the appropriate next steps to take given
significant resource constraints and competing priorities." 90 The
Agency anticipated issuing a proposed rule in spring of 2013
responding to some of the deficiencies identified by the EPA-
OIG.91 As of January 2015, the proposed rule had not been issued
and, according to EPA's website, the proposed rule will focus
solely on "hazardous waste pharmaceuticals that are generated by
healthcare-related facilities." 92
http://www.hercenter.org/hazmat/pharma.cfm#listed (last visited Mar. 23, 2014).
The challenge of evaluating potential harmful qualities of pharmaceutical
substances has been addressed, albeit to a more limited extent, by other federal
agencies. For example, the National Institute for Occupational Safety and Health
(NIOSH) has identified approximately 160 drugs that it states should be handled
as hazardous materials, and the Occupational Safety and Health Administration
(OSHA) lists sixty-one pharmaceuticals on its hazardous drug list. See U.S.
DEP'T OF HEALTH & HUMAN SERV., PUB. NO. 2012-150, NIOSH LIST OF
ANTINEOPLASTIC AND OTHER HAZARDOUS DRUGS IN HEALTHCARE SET7INGS
(2012), available at http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-
150.pdf, U.S. DEP'T OF LABOR, OSHA TECHNICAL MANUAL (OTM), SOME
COMMON DRUGS CONSIDERED HAZARDOUS § VI: ch. 2, app. VI: 2-1 (1999),
available at https://www.osha.gov/dts/osta/otm/otmvi/otm vi_2.html#app_Vl:
2 1.
88 Cf EPA-OIG 2012 REPORT, supra note 84, at 7.
89 See id Among other factual findings, EPA-OIG identified three
pharmaceuticals currently regulated by EPA under RCRA's "toxic" criteria (U-
list), but that actually met RCRA's "acutely" toxic standards (P-list). OIG also
distinguished twenty-one other pharmaceuticals that currently are not regulated
by EPA, but which may qualify as "toxic" under EPA's RCRA criteria. Id. at 7-
8.
90 Id. at 17.
91 Id. at 18.
92 Management of Haz'ardous Waste Pharmaceuticals, U.S. ENVTL. PROT.
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RCRA was never intended to apply to pharmaceutical
hazardous wastes. While EPA has attempted to interpret and
implement the statute with regard to pharmaceutical pollutants,
those efforts will likely prove fruitless.
B. Clean Water Act
The CWA was intended "to restore and maintain the
chemical, physical, and biological integrity of the Nation's
waters." 93 Functionally, CWA requires each state to designate
water quality standards or allowable uses (e.g., domestic water
supply, recreation, propagation of fish and aquatic life, etc.) for all
rivers, streams, and lakes within its jurisdiction.94 These standards
and uses must be based on the National Recommended Water
Quality Criteria 95 and are subject to EPA approval. 96 Once EPA
approves water quality standards or designated uses, "impaired"
bodies of water-those that do not meet the designated water
quality or use standards-are monitored and pollution discharges
strictly regulated by EPA or an authorized state agency.97 These
actions are implemented in relation to each impaired water body's
ability to absorb specific pollutants-total maximum daily load
(TMDL)-without exceeding the designated water quality or use
standards.98 Pollution discharges are managed through the
National Pollutant Discharge Elimination System (NPDES), 99 a
AGENCY, http://www.epa.gov/osw/hazard/generation/pharmaceuticals.htm (last
updated Jan. 1, 2015).
93 33 U.S.C. § 1251(a) (2012).
94 See4OC.F.R. § 130.10 (2014).
95 33 U.S.C. §§ 1313-1314 (2012). National Recommended Water Quality
Criteria are standards developed by EPA, per 33 U.S.C. §§ 1313-1314 (2012),
that provide guidance for states in their development of state-specific water
quality standards. See National Recommended Water Quality Criteria, U.S.
ENVTL. PROT. AGENCY, http://water.epa.gov/scitech/swguidance/standards/
criteria/current/index.cfm (last updated Dec. 3, 2014).
96 40 C.F.R. § 131.5, 131.21 (2014).
97 33 U.S.C. § 1314(l)(1) (2012).
98 33 U.S.C. § 1313(d)(1)(C) (2012) provides that the TMDL "shall be
established at a level necessary to implement the applicable water quality
standards with seasonal variations and a margin of safety which takes into
account any lack of knowledge concerning the relationship between effluent
limitations and water quality."
99 33 U.S.C. § 1342 (2012). Implementation and oversight of the NPDES
permit program has been delegated to authorized state agencies in forty-six
states. National Pollutant Discharge Elimination System (NPDES): State
Program Status, U.S. ENVTL. PROT. AGENCY, http://water.epa.gov/polwaste/
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permit system that allows private, governmental, and other
dischargers to release certain pollutants into designated surface
water bodies. 00 Those discharges are subject to strict discharge
quantity and concentration limitations and waste treatment
technology requirements.101 Absent an NPDES permit, discharges
are strictly prohibited. 10
Despite its potential relevance, the CWA's applicability to
pharmaceutical substances in the environment is limited at best.
With two minor exceptions, 10 3 EPA has never developed water
quality criteria or standards under the CWA for pharmaceuticals,
pharmaceutical wastes, or pharmaceutical residues, and NPDES
permits do not currently include any limitations on the discharge
of pharmaceutically active pollutants. 104 Nevertheless, like RCRA,
the CWA was not designed to address pharmaceutical pollutants.
Given the challenge of assessing tens of thousands of
pharmaceutical products and components, and then implementing
hundreds (if not thousands) of different technology and
management standards, the task will likely be an exercise in
futility. In addition, the Act's key regulatory provisions exclude
npdes/basics/NPDES-State-Program-Status.cfm (last updated Sept. 9, 2014). In
those states, the NPDES permit is issued directly by the authorized state agency.
For example, in Texas, the permit is designated as the Texas Pollutant Discharge
Elimination System permit. What Is the "Texas Pollutant Discharge Elimination
System (TPDES)? ", TEXAS COMM'N ON ENVTL. QUALITY, http://www.
tceq.state.tx.us/permitting/wastewater/pretreatment/tpdes-definition.html (last
updated Nov. 6, 2014).
100 40 C.F.R. § 230.12 (2014) (describing the NPDES permitting system); 40
C.F.R. § 230.3(s) (2014) (defining "waters of the United States").
101 See 33 U.S.C. § 1342(p)(3) (2012) (referring to 33 U.S.C. § 1311 (2012)
for the specific discharge limitations).
102 Id.; 40 C.F.R. § 230.12 (2014).
103 EPA's current national criteria provide both human health and aquatic life
criteria for lindane, an organochlorine, and malathion, an organophosphate
insecticide; both are used to treat lice, as well as in agriculture as an insecticide.
National Recommended Water Quality Criteria, U.S. ENVTL. PROT. AGENCY,
http://water.epa.gov/scitech/swguidance/standards/criteria/current/index.cfm (last
visited Mar. 2, 2015) (listing human health criteria for lindane and malathion);
National Recommended Water Quality Criteria, U.S. ENVTL. PROT. AGENCY,
http://water.epa.gov/scitech/swguidance/standards/criteria/current/index.cfm (last
visited Mar. 23, 2014) (listing aquatic life criteria for lindane and malathion).
104 See U.S. GOv'T. ACCOUNTABILITY OFFICE, GAO-11-346, ACTION NEEDED
TO SUSTAIN AGENCIES' COLLABORATION ON PHARMACEUTICALS IN DRINKING
WATER 11 (2011) [hereinafter USGAO-ACTION NEEDED], available at
http://www.gao.gov/new.items/dI1346.pdf, (bolstering Eckstein and Sherk's
assessment).
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nonpoint sources of waste, 105 which may be significant sources of
the pharmaceuticals found in the environment.10 6
C. Safe Drinking Water Act
The SDWA is designed to protect the quality of the nation's
drinking water and authorizes the EPA to set national standards for
drinking water quality and contaminant regulation in public water
systems and their sources. 107 Known as National Primary Drinking
Water Regulations (NPDWRs), these health-based standards are
legally enforceable maximum levels for specific contaminants in
public water systems. 108 If maximum contaminant levels cannot be
determined, NPDWRs can mandate water treatment procedures
and techniques designed to remove contaminants. 0 9 Under the
SDWA, EPA must develop a Contaminant Candidate List (CCL)
identifying contaminants not presently subject to an NPDWR, but
that "are known or anticipated to occur in public water systems"
and that may require a national drinking water regulation in the
future. ' 10
While EPA has established NPDWRs for more than ninety
contaminants,"' it has never done so for a pharmaceutical.
105 See Michael C. Blumm & William Warnock, Roads Not Taken: EPA vs.
Clean Water, 33 LEWIS & CLARK ENVTL. L. 79, 82 (2003).
106 Cf Daughton & Temes, supra note 2, at 909, 923 (noting that
pharmaceuticals in the environment originate, in part, from terrestrial run-off
from animal husbandry, aquaculture, and excrement of domesticated animals);
See Blumm & Warnock, supra note 105, at 82 (asserting that "today nonpoint
sources contribute more pollution to the nation's waters than point sources, and
in the rural West, nonpoint source pollution is the overwhelming source of water
pollution").
107 40 C.F.R. § 141.1 (2014). NPDWRs include eighty-five standards divided
into six categories: disinfectants, disinfection byproducts, inorganic chemicals,
microorganisms, organic chemical, and radionuclides. Id. §§ 141.50-55.
108 42 U.S.C. § 300g-l(b)(1) (2012).
109 42 U.S.C. § 300g-l(b)(7).
110 42 U.S.C. § 300g-l(b)(l)(B)(i). Unregulated contaminants are placed on
the CCL where:
i) the contaminant may have an adverse effect on the health of persons;
ii) the contaminant is known to occur or there is a substantial likelihood
that the contaminant will occur in public water systems with a
frequency and at levels of public health concern; and iii) in the sole
judgment of the Administrator, regulation of such contaminant presents
a meaningful opportunity for health risk reduction for persons served
by public water systems.
42 U.S.C. § 300g-l(b)(l)(A).
111 Drinking Water Contaminants, ENVT'L PROT. AGENCY, http://water.
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Moreover, until quite recently, it had never placed a
pharmaceutical on the CCL. In August 2008, EPA issued its third
CCL listing 104 chemicals or chemical groups and twelve
microbiological contaminants."l 2 During the preparation stage,
EPA identified 287 pharmaceuticals for possible inclusion in the
CCL; however, all but one were removed prior to list
finalization."13 The sole pharmaceutical substance listed as an
unregulated contaminant was nitroglycerin, a volatile substance
known better for its use in the production of explosives and rocket
propellants, but also used medically to treat heart conditions. 114
Not surprisingly, EPA included it in the CCL primarily because of
environmental and water quality concerns arising from its use as
an explosive." 15
In 2009, the Science Advisory Board Drinking Water
Committee of the EPA Office of Ground Water and Drinking
Water recommended changes to the CCL selection process:
There are also some clear categories of contaminants that need
special attention in selecting the CCL including
pharmaceuticals, personal care products, endocrine disruptors,
antibiotics, and algal toxins. Such contaminants may warrant
changes in the CCL selection processes. General exposure to
even low levels of antibiotics in drinking water, for example,
may lead to antibiotic-resistant pathogens either in a person
drinking the water or the general environment. The current
CCL process for chemicals would not identify this as an
epa.gov/drink/contaminants/#List (last updated Oct. 29, 2014).
112 Drinking Water Contaminant Candidate List 3, 74 Fed. Reg. 51,850 (Oct.
8, 2009).
113 See Pharmaceuticals in the Nation 's Water: Assessing Potential Risks
and Actions to Address the Issue Before the Transp. Safety, Infrastructure Sec.
and Water Subcomm. of the Comm. on Env 't and Public Works U.S. Senate,
110th Cong. 10 (2008) (statement of Benjamin H. Grumbles, Assistant
Administrator for Water, Environmental Protection Agency), available at http://
epw.senate.gov/public/index.cfm?FuseAction=Files.View&FileStoreid=7f39d9
2b-3089-4703-9063-e5d6cl381332.
114 MedlinePlus, Nitroglycerin, U.S. NAT'L LIBR. MED. & NAT'L INST.
HEALTH, http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601086.html (last
updated Aug. 1, 2010); Nitroglycerin, NEW WORLD ENCYCLOPEDIA,
http://www.newworldencyclopedia.org/p/index.php?title=Nitroglycerin&oldid=6
81895 (last updated Apr. 2, 2008).
115 Jeff Donn et al., No Standards to Test for Drugs in Water, ASSOCIATED
PRESS (Mar. 11, 2008), http://www.foxnews.com/printer-friendlywires/
2008Marl 1/0,4675,PharmaWaterlll,00.html.
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adverse effect." 16
In addition, in August 2011, Government Accountability
Office (GAO) recommended that EPA establish a formal
mechanism for federal agencies to collaborate and coordinate
research on pharmaceuticals in the nation's drinking water." 7 In
2012, EPA responded by organizing an inter-agency working
group composed of EPA (Office of Water), U.S. Department of
Agriculture (Agricultural Research Service), U.S. Department of
Health and Human Services (Food and Drug Administration), and
U.S. Department of Interior (U.S. Geological Survey). 118 The
purpose of this collaboration is, partly, to aid EPA evaluate which,
if any, pharmaceutical contaminants should be regulated under
SDWA.119
While certainly a logical effort, the SDWA suffers from the
same ailment afflicting the RCRA and CWA. The statute was
never intended to respond to the tens of thousands of
pharmaceutical pollutants that plague the environment, and it is
questionable whether it could ever do so successfully. In addition,
the SDWA exclusively targets the protection of drinking water
sources for human consumption. Accordingly, its scope excludes
broader environment concerns including known hazards that
pharmaceutical pollutants pose to many aquatic and terrestrial
species.
D. National Environmental Policy Act
In contrast to the above three federal statutes, which focus on
pollutants in the waste stream, NEPA imposes procedural
requirements on federal actions and decision making. NEPA
mandates that all federal agencies consider the significant
116 EPA Sci. ADVISORY BD. DRINKING WATER COMM., SAB ADVISORY ON
EPA's DRAFT THIRD DRINKING WATER CONTAMINATION CANDIDATE LIST (CCL
3) 7 (2009).
117 USGAO-ACTION NEEDED, supra note 104, at 41.
118 Memorandum of Understanding on Sustainability of Federal
Collaboration on Pharmaceuticals in Drinking Water between the U.S.
Environmental Protection Agency (EPA) Office of Water (OW); U.S.
Department of Agriculture (USDA) Agricultural Research Service (ARS); U.S.
Department of Health and Human Services (HHS) Food and Drug
Administration (FDA); and U.S. Department of Interior (DOI) U.S. Geological
Survey (USGS) (Nov. 29, 2012), available at http://water.epa.gov/scitech/
swguidance/ppcp/upload/moupharmdrinkingwaterl 2182012.pdf.
119 ld. at 2.
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environmental impacts of their proposed major actions and
publically disclose the results of their assessments prior to carrying
out those actions. 120 If a preliminary environmental assessment
(EA) indicates that the action could significantly affect the quality
of the human environment, a more rigorous environmental impact
statement (EIS) is required.121 NEPA does not dictate whether or
not a project should be pursued; rather, its chief objective is to
require the federal government to take a "hard look," in a public
process, at the possible environmental consequences of proposed
actions. 122
As a federal agency, the U.S. Food and Drug Administration
(FDA) is tasked with ensuring "the safety, effectiveness, quality,
and security of human and veterinary drugs, vaccines, and other
biological products, and medical devices" in the United States. 123
This includes regulating, reviewing, and approving or denying new
drugs and related pharmaceutical products. 1 24 Accordingly, NEPA
should cover the FDA's actions and decision making as they relate
to pharmaceutical products.
Despite NEPA's applicability to FDA's oversight of
pharmaceuticals, NEPA allows federal agencies to categorically
exclude certain classes of actions from the Act's procedural
requirements on grounds that "as a class, these actions,
120 See Bait. Gas & Elec. Co. v. Natural Res. Def. Council, Inc., 462 U.S. 87,
97 (1983). Under 40 C.F.R. § 1508.18 (2014), "major federal actions" can
include:
new and continuing activities, including projects and programs entirely
or partly financed, assisted, conducted, regulated, or approved by
federal agencies; new or revised agency rules, regulations, plans,
policies, or procedures; and legislative proposals ... [but not] funding
assistance solely in the form of general revenue sharing funds,
distributed undet the State and Local Fiscal Assistance Act of 1972...
with no Federal agency control over the subsequent use of such
funds ... [or] bringing judicial or administrative civil or criminal
enforcement actions.
121 See COUNCIL ON ENVTL. QUALITY, A CITIZEN'S GUIDE TO THE NEPA:
HAVING YOUR VOICE HEARD 12 (2007), available at http://www.blm.gov/
pgdata/etc/medialib/blm/nm/programs/planning/planning docs.Par.53208.File.da
t/A Citizens Guide to NEPA.pdf.
122 See Kleppe v. Sierra Club, 427 U.S. 390, 410 n. 21 (1976).
123 FDA Fundamentals, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
aboutfda/transparency/basics/ucm192695.htm (last updated June 12, 2014).
124 What Does FDA Regulate?, U.S. FOOD & DRUG ADMIN., http://
www.fda.gov/AboutFDA/Transparency/Basics/ucm194879.htm (last updated
Nov.18, 2014).
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individually or cumulatively, do not significantly affect the quality
of the human environment."' 125 Currently, FDA's activities are
ordinarily excluded from NEPA's EA requirements if they fall
within any one often categories listed in 21 C.F.R. § 25.3 1(a)-(j).
These exclusions include new drugs whose residual aquatic
presence does not exceed one part per billion, investigational new
drugs, and substances that occur naturally in the environment. 126
While potentially innocuous, these categorical exclusions, as
applied to pharmaceutical-related actions and decisions, have
allowed an untold number of drugs and related products to
circumvent the NEPA process. If the NEPA procedures had not
been bypassed, information about the drugs and related products
125 21 C.F.R. § 25.10(c) (2014); 40 C.F.R. §. 1508.4 (2014); U.S. DEP'T OF
HEALTH & HUMAN SERVS., GUIDANCE FOR INDUSTRY: ENVIRONMENTAL
ASSESSMENT OF HUMAN DRUG AND BIOLOGICS APPLICATIONS 2 (1998)
[hereinafter HHS GUIDANCE FOR INDUSTRY].
126 See HHS GUIDANCE FOR INDUSTRY, supra note 125, at 2. The complete
list of exclusions is:
(a) Action on [a new drug application] ... abbreviated application,
application for marketing approval of a biologic product, or a
supplement to such applications ... if the action does not increase the
use of the active moiety.
(b) Action on [a new drug application] ... abbreviated application, or a
supplement to such applications ... if the action increases the use of
the active moiety, but the estimated concentration of the substance at
the point of entry into the aquatic environment will be below I part per
billion.
(c) Action on [a new drug application] ... abbreviated application,
application for marketing approval of a biologic product, or a
supplement to such applications ... for substances that occur naturally
in the environment when the action does not alter significantly the
concentration or distribution of the substance, its metabolites, or
degradation products in the environment.
(d) Withdrawal of approval of [a new drug application] or an
abbreviated application.
(e) Action on [investigational new drug applications].
(I) Testing and release by the Food and Drug Administration of lots or
batches of a licensed biologic product.
(g) Establishment of bioequivalence requirements for a human drug or
a comparability determination for a biologic product subject to
licensing.
(h) Issuance, revocation, or amendment of a standard for a biologic
product.
(i) Revocation of a license for a biologic product.
(j) Action on an application for marketing approval for marketing of a
biologic product for transfusable human blood or blood components
and plasma.
21 C.F.R. §§ 25.31 (a)-(j) (2014).
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might have filled many of the knowledge gaps that currently exist,
including on potential hazards from human and environmental
exposure to those substances.
Moreover, some of the categories subject to exclusion from
NEPA may be inappropriate given the state of the science. For
example, the exclusion in 21 C.F.R. § 25.31(b) for drugs whose
projected residue concentration reaching the environment is below
one part per billion is woefully inadequate given that certain
contaminants, such as estrogen and trebolone metabolites, have a
detrimental impact on aquatic species at detection levels of parts
per trillion. 127 While the direct impact here is on aquatic species,
the mutation and potential loss of certain species could have
significant consequences for the quality of the human
environment. 128 The exclusion for substances that occur naturally
in the environment is also questionable because it ignores the
consequence of cumulative and chronic exposure to such
substances by aquatic and other species, including humans, as well
127 See WU ET AL., supra note 21, at 5 (noting that laboratory studies
conducted on the synthetic estrogen, ethinylestradiol, predict that a concentration
of 0.1 ng/L [0.1 part per trillion] in surface water could induce male rainbow
trout to produce the female egg protein vitellogenin); Durhan, supra note 57, at
67 (citing research by Ankely and Jensen K finding that exposure to trenbolone
metabolites in nanogram per liter [equivalent of one part per trillion]
concentration can result in masculinization of fish); Bethany Halford, Side
Effects, 86 CHEMICAL & ENGINEERING NEWS 13, 13 (2008), available at
http://cen.acs.org/articles/86/i8/Side-Effects.html (reporting on research
indicating that the feminization of male fish can occur due to estrogen exposure
at concentrations of parts-per-trillion); see also Shawna Bligh, Pharmaceuticals
in Surface Waters: Use of NEPA, 24 NAT. RES. & ENV'T 56, 56-57 (2009)
(noting that "certain pharmaceuticals, such as hormone-regulating drugs, can
take effect at concentrations as low as a few nanograms per liter" and that
"[t]hese compounds alter sex characteristics of certain fish at concentrations as
low as 20 parts per trillion"); Kidd, supra note 54 (reporting that chronic
exposure over seven years of fathead minnows to low concentrations (5-6 part
per trillion) of the estrogen 17a-ethynylestradiol led to the feminization of males,
and nearly caused the extinction of the fathead minnows population studied).
128 See Toby K. L. Morgan, Down the Drain: Pharmaceutical Waste
Disposal in the United States, 22 FORDHAM ENVTL. L. REV. 393, 430 (2011)
("This then begs the question of whether mutations and spawning abnormalities
in aquatic life significantly affect the quality of the human environment under
NEPA therefore necessitating an amendment of the one ppb categorical
exclusion currently in place."). It is noteworthy that the European Agency for the
Evaluation of Medicinal Products proposed a trigger value of ten parts per
trillion. Christian G. Daughton, Cradle-to-Cradle Stewardship of Drugs for
Minimizing Their Environmental Disposition While Promoting Human Health. L
Rationale for and Avenue Toward a Green Pharmacy, Il1 ENVTL. HEALTH
PERSP. 757, 760 (2003).
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as the possible synergistic outcomes of these substance's
interaction with other chemicals. 1
29
Not all FDA actions are subject to NEPA categorical
exclusions. For example; "[a]pproval of [new drug applications],
abbreviated applications, applications for marketing approval of a
biologic product, supplements to such applications, and actions on
[investigational new drug]" are not excluded unless they
specifically fall under §25.3 1(a), (b), (c), (e), or (1). 130 In addition,
21 C.F.R. § 25.20 specifies certain proposed actions that
"ordinarily require[] at least the preparation" of an EA.'31 More
generally, FDA must file an EIS when the agency determines,
through the preparation of an EA, that "a proposed action may
significantly affect the quality of the human environment." 32
Nevertheless, FDA's regulatory interpretation and
implementation of NEPA have substantially neutered the Act's
procedural requirements as they apply to the agency and its
activities. For example, FDA regulations provide that "[t]here are
no categories of agency actions that routinely significantly affect
the quality of the human environment and that therefore ordinarily
require the preparation of an EIS."'133 Moreover, since a significant
proportion of the agency's activities are excluded from the EA
requirement, few of FDA's activities are subjected to the scrutiny
of either an EA or an EIS. 134 In fact, since NEPA's enactment in
1970, the FDA has only performed one EIS related to human
medicines. That EIS addressed chlorofluorocarbons used as
129 See supra notes 48-52, 61 and accompanying text.
130 21 C.F.R. § 25.20(1) (2014).
131 § 25.20. Unless otherwise categorically excluded, proposed actions that
ordinarily require at least the preparation of an EA include, inter alia: major
legislative recommendations or reports prepared for Congress related to
pharmaceuticals; regulations for labeling requirements or for standards related to
pharmaceuticals; exemptions and variances from FDA regulations; establishment
of a tolerance for unavoidable poisonous or deleterious substances in food or in
packaging materials to be used for food; approval of new drug applications,
abbreviated applications, applications for marketing approval of a biologic
product, supplements to such applications, and actions on investigational new
drugs; approval of new animal drug applications, abbreviated applications,
supplements, actions on investigational new animal drugs. §§ 25.20(a), (f), (g),
(), (1), & (m).
132 § 25.22(b).
133 § 25.22(a).
134 The only exception to the categorical exclusions is a finding that
"extraordinary circumstances" suggesting a significant effect on the human
environment. § 25.21.
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propellants in self-pressurized or aerosolized containers in
products subject to the Federal Food, Drug, and Cosmetic Act.' 35
Even if a particular FDA action was subjected to EIS scrutiny,
FDA regulations thwart the very NEPA process mandated for
nearly every other federal regulatory action across the U.S.
government. Under FDA regulations implementing NEPA, an EIS
"will become available only at the time of the approval of the
product[J"' 136 and public comments are accepted only after an EIS
is released. 37 Moreover, where public comments are submitted to
the agency, they can be used solely "as a basis" for the agency to
consider withdrawal of approval. 138 In other words, FDA rules
effectively remove EIS consideration from the agency's decision-
making process since the decision to act would have been made in
advance of and absent public participation. While courts will
likely defer to agency interpretation under Chevron U.S.A. v.
Natural Resources Defense Council,139 it is difficult to have faith
in a process that appears to employ NEPA merely as a perfunctory
procedural step. By delaying publication of the EIS, FDA is
effectively undermining NEPA's fundamental and critically
important purpose of informed decision making and public
participation. 140
135 See Temes & Joss, supra note 11, at 112. In 1978, FDA prepared a
programmatic EIS regarding a proposed ban on the use of chlorofluorocarbons
as propellants in self-pressurized containers of various food and pharmaceutical
products. In that EIS, FDA concluded that such use "poses an unreasonable risk
of long-term biological and climatic impacts" because of the impact
chlorofluorocarbons had on the ozone layer. U.S. FOOD & DRUG ADMIN.,
FLUOROCARBONS: ENVIRONMENTAL AND HEALTH IMPLICATIONS: FINAL
ENVIRONMENTAL IMPACT STATEMENT PREPARED IN ACCORDANCE WITH SECTION
102(2)(C) OF P.L. 91-190, at iii (1978).
136 § 25.52(a).
137 § 25.52(b).
138 Id.
139 Chevron U.S.A. v. Natural Res. Def. Council, 467 U.S. 837 (1984).
Under Chevron, courts should defer to agency statutory interpretation unless
Congress has expressed unambiguous intent regarding the precise question at
issue or the agency's answer is not based on a permissible construction of the
statute. Id. at 842-43.
140 Generally, NEPA requires federal agencies to complete and publish an
EIS and consider public comments prior to taking a final agency action. See
COUNCIL ON ENVTL. QUALITY, supra note 121, at 13-18. On the value of public
participation in NEPA decision making, see William Murray Tabb, The Role of
Controversy in NEPA: Reconciling Public Veto with Public Participation in
Environmental Decisionmaking, 21 WM. & MARY ENVTL. L. & POL'Y REV. 175
(1997) and Nancy Perkins Spyke, Public Participation in Environmental
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In addition, FDA's justification for its unconventional
interpretation and implementation of the NEPA requirements may
no longer pass muster. In the FDA's final rule introducing the
categorical exclusions, the agency explained that those exclusions
were based on a presumption that the excluded classes of actions
will "not individually or cumulatively have a significant effect on
the human environment."1 41 Essentially, the agency contended that
few if any pharmaceutical-related activities and decisions-
including new drug approvals and changes to existing authorized
drug uses-would detrimentally affect the environment. Given the
state of science and what is now known about the effect of many
pharmaceuticals on the natural environment, and possibly on the
human environment, 142 that presumption is no longer convincing
or legally defensible.
E. Secure and Responsible Drug Disposal Act
In 2010, Congress enacted the Secure and Responsible Drug
Disposal Act (SRDDA), ]43 primarily as a means to respond to the
misuse of pharmaceuticals "particularly among teenagers."' 44
Legislators also recognized the value of proper drug disposal for
protecting the environment from pharmaceutical pollutants. 45
Accordingly, the SRDDA authorized the U.S. Drug Enforcement
Administration (DEA) to promulgate regulations that would
expand the options available for the collection and proper disposal
of unused controlled substances 146 to designated entities for proper
Decisionmaking at the New Millennium: Structuring New Spheres of Public
Influence, 26 B.C. ENVTL. AFF. L. REV. 263 (1999).
141 National Environmental Policy Act; Revision of Policies and Procedures,
62 Fed. Reg. 40,570, 40,591 (July 29, 1997).
142 See supra note 43-61 and accompanying text.
143 Secure and Responsible Drug Disposal Act of 2010, Pub. L. No. 111-273,
124 Stat. 2858 (2010).
-144 Id. § 2(l).
145 In its perambulatory findings, Congress acknowledged that:
Individuals seeking to reduce the amount of unwanted controlled
substances in their household consequently have few disposal options
beyond discarding or flushing the substances, which may not be
appropriate means of disposing of the substances. Drug take-back
programs are also a convenient and effective means for individuals in
various communities to reduce the introduction of some potentially
harmful substances into the environment, particularly into water.
Id. § 2(4)(C).
146 Controlled substances, generally, are drugs subject to government
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disposal. 147
In response, on September 9, 2014, DEA issued new rules
allowing consumers to deliver illegal and prescription medication
to drug manufacturers, distributors, and reverse distributors,
narcotic treatment programs, hospitals and clinics with on-site
pharmacies, and retail pharmacies. 148 Authorized delivery and
collection methods include take-back and mail-back programs and
designated collection receptacles. 149
While the new rule is certainly welcome, it is still early to
assess whether it will succeed in diminishing the volume of
pharmaceuticals that reach the environment, let alone those that
are illicitly distributed. The opportunities created under the new
rules are entirely voluntary and all costs and liabilities are to be
borne directly by authorized collectors.150  Whether the
pharmaceutical industry willingly accepts this responsibility
remains to be seen.
In addition, the new rules may have cancelled DEA's
relatively successful national drug "take-back" event aimed at
reducing the number of unwanted, expired, or unused medications
in the home. 15' On September 23, 2014, the agency held its ninth,
and possibly last, national event, which netted 617,150 pounds of
expired and unwanted medications at 5,495 take-back sites
nationwide. 152 Between September 2010 and September 2014, the
regulations and include illegal drugs and prescription medication, such as
Ambien, oxycodone, and codeine. See 21 U.S.C. § 802(6) (2012) (defining
"controlled substance" as "a drug or other substance, or immediate precursor"
that is subject to the Controlled Substances Act); U.S. DRUG ENFORCEMENT
ADMIN., LISTS OF: SCHEDULING ACTIONS, CONTROLLED SUBSTANCES,
REGULATED CHEMICALS (2014). Under DEA regulations, controlled substances
are drugs that have some potential for abuse or dependence. See Controlled
Substance Schedules, U.S. DRUG ENFORCEMENT ADMIN., http://www.
deadiversion.usdoj.gov/schedules/index.html (last visited Mar. 23, 2014).
147 Pub. L. No. 111-273 § 3(a).
148 Disposal of Controlled Substances, 79 Fed. Reg. 53,520 (Sept. 9, 2014).
149 79 Fed. Reg. at 53,521.
150 See infra notes 218-221 and accompanying text.
151 See News Releases, U.S. DRUG ENFORCEMENT ADMIN., http://www.
deadiversion.usdoj.gov/drugdisposal/takeback/newsrelease.htm (last visited
Jan. 07, 2015) (providing news releases discussing eight take back events
between October 2010 and November 2014).
152 See DEA and Partners Collect 309 Tons of Pills on Ninth Prescription
Drug Take-Back Day, U.S. DRUG ENFORCEMENT ADMIN., (Nov. 5, 2014),
http://www.dea.gov/divisions/hq/2014/hq 110514.shtml [hereinafter Ninth
Prescription Take-Back Day] (referencing the ninth take-back program); DEA 's
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program removed over 4.8 million pounds of pharmaceuticals
from circulation. 153 Accordingly to the DEA, it has "no plans to
sponsor more nationwide Take-Back Days in order to give
authorized collectors the opportunity to provide this valuable
service to their communities."' 154
III. THE STATE APPROACH TO MANAGING PHARMACEUTICALS IN THE
ENVIRONMENT
A. Managing Pharmaceutical Wastes
Under RCRA, the EPA permits states to develop and
implement their own hazardous waste management programs so
long as the programs are no less stringent than the federal
program. 55 The adoption of state-specific programs has resulted in
a myriad of different standards, compliance criteria, and other
regulatory variations among the states and between the states and
EPA.
For example, Connecticut, Michigan, Oregon, Rhode Island,
and Vermont have adopted regulations designating certain non-
RCRA wastes as hazardous wastes.156 Similarly, California created
Ninth and Final Prescription Drug Take Back Day Being Held Saturday
September 27, U.S. DRUG ENFORCEMENT ADMIN., (Sept. 23, 2014),
http://www.dea.gov/divisions/hq/2014/hq092314.shtml [hereinafter Final
Prescription Drug Take-Back Day] (suggesting that this ninth event may be the
"final" DEA national take back event).
153 See Ninth Prescription Take-Back Day, supra note 152.
154 Final Pres~ription Drug Take Back Day, supra note 152.
155 See 42 U.S.C. § 6926(b) (2012); John Johnson et al., Challenges in
Pharmaceutical Waste Management: "First, Do No Harm", 26 NAT.
RESOURCES & ENV'T 1, 5 (2012). With the exception of Alaska and Iowa, every
state has developed and implemented its own hazardous waste management
program. See U.S. ENVTL. PROT. AGENCY, AUTHORIZATION STATUS BY RULE:
STATS DATA AS OF JUNE 30, 2014 (2014), available at
http://www.epa.gov/epawaste/laws-regs/state/stats/authall.pdf.
156 For Connecticut regulations, see CONN. GEN. STAT. § 22a-454 (2014) and
Non-RCRA Hazardous Waste (Connecticut Regulated Waste), CONN. DEP'T OF
ENERGY & ENVTL. PROT., http://www.ct.gov/DEep/cwp/view.asp?a=2718&q=
325428&deepNavGID=1967 (last updated Feb. 20, 2013). For Michigan
regulations, see MICH. ADMIN. CODE r. 299.9228 (2013). See also infra note 160
and accompanying text. For Oregon regulations, see OR. DEP'T OF ENVTL.
QUALITY, OREGON "STATE-ONLY" HAZARDOUS WASTE CODES (2008), available
at http://www.deq.state.or.us/lq/pubs/docs/hw/Reporting/OregonWasteCodes.pdf For
Rhode Island regulations, see 2014 R.I. Gov't Reg. 5502 (LexisNexis January
2014), available at http://www.dem.ri.gov/pubs/regs/regs/waste/hwregs07.pdf.
For Vermont regulations, see 7-1-9 VT. CODE R. (2013), available at
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a new category of non-RCRA wastes called "biohazardous waste,"
a subset of "medical waste," that is regulated as Califomia-only
hazardous wastes and which applies to all licensed health-care
facilities, regardless of amount of waste produced, as well as
anyone else who produces more than one hundred kilograms of
infectious waste per month. 57 In contrast, Minnesota expanded its
hazardous waste definition by adding lethality to the four RCRA
hazardous waste characteristics, 158 while Florida and Michigan
extended RCRA's universal waste program-a streamlined RCRA
disposal program designed to facilitate the proper collection and
recycling or treatment of certain common, widely generated,
hazardous wastes' 59-to pharmaceutical hazardous waste. '
60
In addition, many states have adopted inconsistent
implementation strategies of RCRA regulations and EPA
interpretations. For example, EPA excludes certain pharmaceutical
waste from RCRA disposal regulation. 16 1 These interpretative
exclusions are not binding on states that have implemented their
own hazardous waste management programs. 162 Accordingly,
while many states have adopted EPA's exclusions in their entirety,
others have adopted them selectively or not at all. Connecticut and
Michigan, for example, have refused to adopt the epinephrine or
http://www.anr.state.vt.us/dec/wastediv/rcra/regs.htm. See also State-Specific
Universal Waste Regulations, U.S. ENVTL. PROT. AGENCY,
http://www.epa.gov/osw/hazard/wastetypes/universal/statespf.htm (last updated
June 13, 2014).
157 Medical Waste Management Act, CAL. HEALTH & SAFETY CODE §§
117600-118360 (describing a standard that is quite different from the federal
program described in Section Ill.a).
158 See MINN. R. 7045.0131(6) (2013); see also MINN. POLLUTION CONTROL
AGENCY, THE LETHALITY CHARACTERISTIC: A MINNESOTA-SPECIFIC
HAZARDOUS-WASTE CHARACTERISTIC (2009), available at http://www.pca.state.
mn.us/index.php/view-document.html?gid=4002.
159 The RCRA Universal Waste Rule applies to certain common, widely
generated hazardous waste that can be managed under a streamlined disposal
program designed to facilitate the proper collection and recycling or treatment of
those wastes. See U.S. ENVTL. PROT. AGENCY, EPA530-K-05-019, TRAINING
MODULE: INTRODUCTION TO UNITED STATES ENVIRONMENTAL PROTECTION
AGENCY UNIVERSAL WASTE (2005), available at http://epa.gov/waste/
inforesources/pubs/training/uwast05.pdf. Under current EPA regulations, the
federal program applies only to certain batteries, pesticides, mercury-containing
equipment, and light bulbs. 40 C.F.R. § 273 (2005).
160 FLA. ADMIN. CODE ANN. r. 62-730.186 (2013); MICH. ADMIN. CODE. r.
299.9228 (2013).
161 See SMITH, supra note 9, at 17-18.
162 Johnson, supra note 155, at 3.
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nitroglycerine federal exclusions, while Washington has declined
to adopt the exclusion for P-listed waste in used syringes. 163
While many of these state-specific approaches and criteria are
more stringent than the federal RCRA program, the differences in
compliance regimes effectively create substantial challenges for
regulated entities with facilities in multiple states to implement
consistent pharmaceutical waste compliance programs. Rather
than raising the bar, the disparate standards, compliance criteria,
and other regulatory variations have resulted in inconsistent and
inadequate monitoring and enforcement. 164
B. Drug Collection and Disposal Programs
In addition to DEA-run drug "take-back" events, several
states have implemented their own collection and disposal
programs. 165 The vast majority of these schemes focus more on
halting the illegal circulation and use of drugs rather than on
preventing their introduction into the environment. 166 To the
extent that there is a reduction in the use of unwanted, unused,
163 Id.
164 E.g., Jason M. Levy, Conflicting Enforcement Mechanisms Under RCRA:
The Abstention Battleground Between State Agencies and Citizen Suits, 39
ECOLOGY L.Q. 373 (2012) (discussing enforcement conflicts in RCRA and other
statutes that authorize multiple enforcement mechanisms, including
implementation and enforcement by states); U.S. ENVTL. PROT. AGENCY, OFFICE
OF INSPECTOR GEN., REPORT No. 12-P-0 113, EPA MUST IMPROVE OVERSIGHT OF
STATE ENFORCEMENT 6 (2011), available at http://www.epa.gov/oig/reports/
2012/20111209-12-P-0113.pdf (discussing EPA's failure to administer
consistent enforcement across the nation of state implementation of the RCRA,
CWA, and Clear Air Act).
165 For a summary of take-back programs in the Great Lakes region, see
PRODUCT STEWARDSHIP INST., PROTECTING OUR HEALTH AND THE
ENVIRONMENT: THE NEED FOR SUSTAINABLY FINANCED DRUG TAKE-BACK
PROGRAMS 8, 12-15 (2012), available at http://www.productstewardship.us/
associations/6596/files/Pharmaceuticas%20White%2Paper/o20on%20EPR Fi
nal.pdf. For summaries of several early drug take-back programs, see MONICA
HUBBARD, OREGON PHARMACEUTICAL TAKE BACK STAKEHOLDER GROUP: FINAL
REPORT 1 (2007), available at http://www.oracwa.org/pdf/oregon-drug-
takeback-report.pdf and Glassmeyer, supra note 20.
166 Cf Christian G. Daughton, Cradle-to-Cradle Stewardship of Drugs for
Minimizing Their Environmental Disposition While Promoting Human Health.
I1. Drug Disposal, Waste Reduction, and Future Directions, 111 ENVTL. HEALTH
PERSP. 775, 780 (2003) (explaining that "[m]ost existing laws directed at drug
disposal are written around two concerns: a) the disposition of 'controlled'
substances, or b) the imperative to keep expired/unwanted medication away from
children (this is perhaps the major imperative for disposing of drugs to sewage
that has been instilled in the public over the years)").
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improperly discarded, and stolen drugs, which are then directed
toward proper disposal, it is logical to assume fewer
pharmaceutical pollutants reach the environment.
Utah operates a drug take-back program, the goal of which is
to "prevent and reduce the misuse and abuse of prescription pain
medications."' 167 The program, however, also recognizes that
"drugs that are disposed by flushing can enter the environment
because sewage treatment plants and septic systems are not
designed to remove them" and that "scientific research suggests
that certain drugs may cause harm to fish and other aquatic
life."168
Maine, which is credited with implementing the first
statewide drug take-back program in 2007, experimented with an
anonymous and no-cost drug mail-back pilot program funded
partly by an EPA grant. 169 The eighteen-month program, which ran
between May 2008 and October 2009, generated 2,373 pounds of
drugs. 170 Due to budgetary concerns and a change in state
government administration, the program was not funded by the
Maine legislature following its expiration. 171 Maine, however,
continues to offer drug drop-off and disposal services. 172
Other states also have initiated various drug take-back and
drop-off program with varying degrees of success. Between 2009
167 Preventing Prescription Drug Overdoses, UTAH DEP'T OF HEALTH,
http://www.health.utah.gov/vipp/topics/prescription-drug-overdoses/prevention.
html (last visited Mar. 2, 2015). Utah's program authorizes a number of
permanent collection sites and continues to organize periodic community take-
back events. Safe Disposal: Learn the Facts, USE ONLY AS DIRECTED,
http://www.useonlyasdirected.org/safe-disposal (last visited July 11, 2014).
168 See Safe Disposal: Learn the Facts, supra note 164. The "Use Only as
Directed" program is "a media and education campaign funded by the Utah
Commission on Criminal and Juvenile Justice and a federal grant awarded to the
Utah Division of Substance Abuse and Mental Health." The Campaign, USE
ONLY AS DIRECTED, http://www.useonlyasdirected.org/campaign (last visited
Mar. 23, 2014).
169 See LENARD KAYE et al., EXECUTIVE SUMMARY: REDUCING PRESCRIPTION
DRUG MISUSE THROUGH THE USE OF A CITIZEN MAIL-BACK PROGRAM IN MAINE
(2010); Brett Walton, Unprescribed: Legislation to Keep Drugs out of Water
Thwarted by U.S. Pharmaceutical Lobbying, CIRCLE OF BLUE (Nov. 10,
2011), http://www.circleofblue.org/watemews/2011 /world/unprescribed-u-s-
pharmaceutical-industry-fights-to-avoid-paying-for-drug-disposal-programs/.
170 KAYE, supra note 169; see Walton, supra note 169.
171 See Walton, supra note 169.
172 Safe Medicine Disposal for ME Program, U ME., http://umaine.edu/
safemeddisposal (last visited Nov. 16, 2014).
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and 2011, Colorado collected twelve thousand pounds of drugs in
a pilot project utilizing only eleven drop-off locations statewide.
During the same time period, the Iowa program generated nearly
21,545 pounds of unwanted, expired, and unused pharmaceutical
products. 173 In 2011, Wisconsin's statewide, take-back program
generated nearly 93,500 pounds of household pharmaceuticals,
although, a subsequent study suggests that this volume was a mere
two percent of the estimated 4.4 million pounds of unwanted
pharmaceuticals in the state that year.' 7
4
Funding is one of the primary challenges facing all of these
programs. 175 While a number of states have proposed initiatives
mandating industry-funded drug collection and disposal programs,
none have passed largely due to industry opposition. 176 Mandated
industry-funded programs in the United States have been
implemented at the local level only in Alameda County, California
and King County, Washington State. 177 The City of San Francisco
implemented a similar program, albeit with voluntary
collaboration of the pharmaceutical industry. 178 Both the Alameda
173 See Walton, supra note 169.
174 U. OF WISC. Coop. EXTENSION & PROD. STEWARDSHIP INST., WISCONSIN
HOUSEHOLD PHARMACEUTICAL WASTE COLLECTION-CHALLENGES AND
OPPORTUNITIES, at v, 5-6, & 39 (2012), available at http://dnr.wi.gov/topic/
HealthWaste/documents/2012HouseholdPharmStudy.pdf. The other ninety-eight
percent "were discarded in the trash, flushed down the drain, abused, or stored
indefinitely in the medicine cabinet." Id. at v.
175 See, e.g., KAYE, supra note 169; Walton, supra note 169 (raising the
funding issue with Maine's program); UNIVERSITY OF WISCONSIN COOPERATIVE
EXTENSION & PRODUCT STEWARDSHIP INSTITUTE, supra note 174, at v (noting
"high costs [and] lack of sustainable funding" as some of the chief barriers for
developing an effective state-wide drug collection program).
176 See Walton, supra note 169.
177 See Brett Walton, Who Will Pay for Disposal? Drug Companies Lose
Against Local Governments in California and Washington, CIRCLE OF BLUE
(Sept. 11, 2013), http://www.circleofblue.org/watemews/2013/world/who-will-
pay-for-drug-disposal/.
178 Press Release, S.F. Dep't of the Env't, San Francisco's Pharmaceutical
Industry Sponsored Unused Medicine Take-Back Program Is Funded for an
Additional Year (Aug. 14, 2013), available at http://www.sfenvironment.org/
news/press-release/san-franciscos-pharmaceutical-industry-sponsored-unused-
medicine-takeback-program-is-funded-for-an-additional-year. San Francisco,
however, is moving to make the program mandatory for drug makers. See Ed
Silverman, That Flushing Sound: San Francisco Moves Closer to a Take-Back
Program, WALL ST. J. (Feb. 27, 2015, 9:00 AM), http://blogs.wsj.com/
pharmalot/2015/02/27/that-flushing-sound-san-francisco-moves-closer-to-a-take-
back-program/.
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County and King County programs have been challenged in court
by the pharmaceutical industry. 7 9
IV. MANAGING PHARMACEUTICALS IN THE ENVIRONMENT: A
LIFECYCLE APPROACH
Given the potential threats pharmaceuticals in the
environment pose to human and environmental health, as well as
the haphazard and inadequate state of the regulatory regime for
managing those threats, it is prudent to question whether
pharmaceuticals and their residues should be regarded as safe until
proven unsafe, or unsafe until proven safe. The answer to this
query, though, is not straightforward. Pharmaceuticals benefit
humans and other species by addressing health problems,
improving quality of life, and even extending life. Yet, they have
the potential to cause great harm to the health of people and
countless other species when improperly released into the
environment. 1 80  Should society continue to produce
pharmaceuticals, even at the possible expense of human and
environmental health? Should we place limitations on
pharmaceuticals to prevent them from reaching the environment,
even if such restrictions raise costs and stifle innovation?
While these two positions-regulating pharmaceuticals will
increase costs and stifle innovation; failing to regulate
pharmaceuticals will harm people and the environment-may
appear mutually exclusive, they need not be entirely incompatible.
The challenge is to find a middle ground that acknowledges and
balances the potential risks associated with pharmaceuticals in the
environment with the likely impacts that policy and legislative
restrictions could have on the pharmaceutical industry. The
challenge is also to find an approach that diminishes the likelihood
that pharmaceutical pollutants will reach the nation's rivers, lakes,
aquifers, and soils, while minimizing additional costs for
pharmaceutical research, production, and distribution to an
acceptable and predictable level. That middle ground may be
179 See Kurt R. Karst, Royal Flush? Trade Groups Challenge a Second Drug
Stewardship Program; This Time the Target is King County, Washington, FDA
L. BLOG (Dec. 17, 2013), http://www.fdalawblog.net/fda law bloghyman_
phelps/2013/12/trade-groups-challenge-a-second-drug-stewardship-program-
this-time-the-target-is-king-county-washing.html; see also infra notes 227-229
and accompanying text (discussing status of these cases).
180 See supra notes.43-61 and accompanying text.
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found by targeting the earlier lifecycle stages of pharmaceuticals
products for regulatory action.
As a policy matter, there are many points in the lifecycle of a
pharmaceutical at which standards -and regulations might be
implemented. C.G. Daughton's chart of the Environmental
Lifecycle of Pharmaceuticals is particularly instructive, albeit
somewhat overwhelming, in that it illustrates the dozens of
interfaces that exist among manufacturing and distribution
companies, medical facilities, individuals, and, disposal and
treatment activities. 18 1 For purposes of relative simplicity,
Daughton's chart can be condensed to the six chief stages in the
lifecycle of a pharmaceutical at which regulatory intervention may
be warranted and applied (see Figure 2). These include design and
manufacturing, retail sale and distribution by health care
professionals, consumer use, product disposal, waste disposal
treatment, and post-disposal treatment.
Figure 2. The six chief stages in the lifecycle of a pharmaceutical at
which regulatory intervention may be warranted and applied
Manufacturing
Retail Sale (e.g., pharmacy) or
Provider (e.g., hospital)
S Consumer Us
Product Disposal
Waste Disposal Treatment
Post-Disposal Treatment
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As indicated above, the current regulatory structure targeting
pharmaceutical pollutants in the environment focuses primarily on
the final two lifecycle stages: waste disposal treatment and post-
disposal treatment. 18 2 Such a narrow approach is both flawed and
inadequate largely because it is doubtful that regulatory-imposed
techniques or processes can be devised to effectively treat or
remove all of the thousands of different pharmaceutical substances
and their varying active ingredients and components at the
disposal and post-disposal stages. 83 Accordingly, targeting the
terminal point of the pharmaceutical lifecycle is unlikely to
achieve much success in terms of eliminating or reducing
pharmaceutical pollutants in the environment. 184 Instead, it may be
182 See supra notes 69-119, 155-162 and accompanying text.
183 See WU ET AL., supra note 21, at 42. It is unlikely that any "single water
treatment process will be capable of reducing all trace organic contaminants to
below increasingly sensitive analytical detection limits." Benjamin D. Stanford et
al., Estrogenic Activity of U.S. Drinking Waters: A Relative Exposure
Comparison, 102 J. AM. WATER WORKS ASS'N 56 (2010). Likewise, Jones states
that "[t]he total costs of removing every possible endocrine disrupting compound
could quickly become astronomical. Although the public may want pure water,
people are not prepared to pay what it would actually cost even if sufficient
technology did exist." Keith J. Jones, Endocrine Disruptors and Risk
Assessment: Potential for a Big Mistake, 17 VILL. ENVTL. L.J. 357, 385-86
(2006); see also Eckstein & Sherk, supra note 5, at 44 (maintaining that
"[i]mposing such costs on the operators of publically-owned treatment works
may be both financially and politically impossible").
184 Pharmaceutical pollutants are often found in very low concentrations,.e.g.,
at the nanogram to low microgram per liter range. See WORLD HEALTH ORG.,
supra note 8, at 5, 15. Some conventional wastewater treatment processes, such
as the use of activated sludge and biofiltration, can remove certain
pharmaceuticals from the waste stream. Results, however, vary and depend on a
variety of factors, including the kind of methodology used and pharmaceutical
pollutant targeted. Advanced wastewater treatment methods, including
ozonation, membrane treatment, and advanced oxidation, have been considerably
more effective at removing certain pharmaceutical pollutants from the waste
stream. Nevertheless, neither conventional nor advanced technology can remove
all pharmaceuticals from the waste stream. Id. at 17, 20-21; NAT'L ASS'N OF
CLEAN WATER AGENCIES & ASs'N OF METRO. WATER AGENCIES,
PHARMACEUTICALS IN THE WATER ENVIRONMENT 19 (2010), available at
https://www.dcwater.com/waterquality/PharmaceuticalsNACWA.pdf, see also
Kummerer, supra note 26, at 412-14 (discussing some of the merits and
shortcomings of various advanced effluent treatment processes). While removal
of some pharmaceutical wastes at the drinking water treatment stage is possible,
such as with methodologies that include chlorination and ozonation, most
existing processes are not designed to remove such pollutants. See WORLD
HEALTH ORG., supra note 8, at 18.
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more prudent to abide by Benjamin Franklin's adage that an ounce
of prevention is worth a pound of cure and focus on the first four
stages of the pharmaceutical lifecycle where mechanisms could be
implemented for minimizing the probability that pharmaceutical
pollutants actually reach the environment.
A. Drug Design and Manufacturing
Pharmaceutical companies tend to focus on efficiency and
economics when manufacturing new drugs and reformulating
existing drugs."8 5 Drug manufacturers, however, should also be
incentivized or required to consider the environmental impacts of
drug use resulting from the accumulation of pharmaceuticals in
soils and fresh water' resources. 8 6 In particular, manufacturers
should target the manufacturing-related causes of these
accumulations.
To reduce the amount of pharmaceutical pollutants that reach
the environment, manufacturers could seek to enhance the
physiological sorption rates of drugs, 187 as well as formulate drugs
that maintain their therapeutic effectiveness at substantially
185 See Jeremy Laurance, Drugs Companies Putting Profit Ahead of Medical
Discoveries, Warn Scientists, INDEPENDENT (Aug. 8, 2012),
http://www.independent.co.uk/life-style/health-and-families/health-news/drugs-
companies-putting-profit-ahead-of-medical-discoveries-wam-scientists-8015784
.html (asserting that drug companies prioritize profits above new discoveries);
John LaMattina, Do Drug Companies Make Drugs, Or Money?, FORBES (July
29, 2014, 9:03 AM), http://www.forbes.com/sites/johnlamattina/2014/07/29/do-
drug-companies-make-drugs-or-money/ (opining that while "[a] pharma
company's business is making drugs ... in doing so it had better make profits");
Big Pharma Spends More on Advertising than Research and Development, Study
Finds, SCIENCEDAILY (Jan. 7, 2008), http://www.sciencedaily.com/releases/
2008/01/080105140107.htm (discussing findings of a study supporting the
proposition that pharmaceutical companies are predominantly marketing-driven).
186 Incentives for pharmaceutical manufacturers could include drug patent
extensions, tax benefits, and reduced environmental testing obligations for
"green" products. See e.g., EUROPEAN ENVTL. AGENCY, PHARMACEUTICALS IN
THE ENVIRONMENT: RESULTS OF AN EEA WORKSHOP, EAA TECHNICAL REPORT
No. 1/2010, at 10 (2010) (discussing patent incentives and different testing
requirements); Daughton, supra note 166, at 776 (discussing patent 'incentives);
Marvin E. Herring et al., Current Regulations and Modest Proposals Regarding
Disposal of Unused Opioids and Other Controlled Substances, 108 J. AM.
OSTEOPATHIC ASS'N 338, 341 (2008) (proposing providing economic incentives
to pharmaceutical manufacturers).
187 See e.g., WU ET AL., supra note 21, at 16; Daughton, supra note 128, at
765.
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reduced dosage levels. 188 They also could develop "smart" drugs
that "better emulate the non-anthropocentric, native chemistries of
natural products"' 189 and design drugs that are specifically tailored
to groups of patients based on physiological traits, such as weight
or genetic predisposition. 190 In addition, manufacturers should
produce certain drugs in multiple formulations and doses so as to
accommodate patients of different ages, sizes, weight, and medical
needs. 9 ' Lastly, they should formulate drugs to be more
susceptible to biodegradation, photolysis, and other
physicochemical alterations that yield less harmful end
products. 192
Without imposing regulatory obligations on the
pharmaceutical industry, it is quite unlikely that drug
manufacturers will pursue these objectives on their own. Absent a
clear business objective or a regulatory mandate, most for-profit
companies are more likely to prioritize their own economic
188 Id. at 766.
189 Id.
190 Id. at 767. Such tailoring increasingly is becoming a reality given
advances in genomics (the study of genes and their functions), proteomics (the
study of proteins and their functions), glycomics (study of the structure and
function of sugars and saccharides), and metabolomics (the study of metabolites
and their functions). Id. at 765; see -Omes and -omics Glossary & Taxonomy:
Evolving Terminology for Emerging Technologies, CAMBRIDGE HEALTHTECH
INST., http://www.genomicglossaries.com/content/omes.asp (last updated Jan.
12, 2015).
191 See L.J. Lesko & S. Schmidt, Individualization of Drug Therapy: History,
Present State, and Opportunities for the Future, 92 CLINICAL PHARMACOLOGY &
THERAPEUTICS 458 (2012) (discussing the evolution and current status of
individualized drug therapy); Su Yasuda et al., The Role of Ethnicity in
Variability in Response to Drugs: Focus on Clinical Pharmacology &
Therapeutics, 84 CLINICAL PHARMACOLOGY & THERAPEUTICS 417, 418, 422
(2008) (noting that while "scientific data demonstrate genetic differences in the
expression of drug-metabolizing enzymes, transporters, and targets," most
recently approved pharmaceuticals were not evaluated for the effect of race or
ethnicity on efficacy or safety); Anne Zajicek et al., A Report from the Pediatric
Formulations Task Force: Perspectives on the State of Child-Friendly Oral
Dosage Forms, 15 AAPS J. 1072 (2013) (noting that "[m]ost medications are
produced for adults as capsules and tablets," that these are "often not suitable for
children," and the "dearth of oral pediatric formulations"); see also supra note
16; cf Christian G. Daughton & Ilene S. Ruhoy, Lower-Dose Prescribing:
Minimizing "'Side Effects " of Pharmaceuticals on Society and the Environment,
443 SCI. TOTAL ENV'T 324 (2013) (discussing dose reduction as a means for
reducing environmental API loadings).
192 See WU ET AL., supra note 20, at 16; Daughton, supra note 128, at 765;
Wennmalm & Gunnarsson, supra note 43, at 296.
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interests over broader societal concerns. While the pharmaceutical
industry probably might oppose it, an effective mechanism for
integrating the environmental impacts of drug use into the drug
design and manufacturing process would be a re-empowered
NEPA process applied to FDA's drug approval process.
As a preliminary matter, FDA should reevaluate its
categorical NEPA exclusions in light of the current state of science
and the tremendous advances made in assessing the consequences
of pharmaceuticals in the environment. These exclusions date back
to 1997193 and are based on outdated scientific information*194 In
particular, the Agency should acknowledge that pharmaceutical
products, wastes, and residues are a source of potentially harmful
environmental pollutants. This recognition should encompass the
individual, cumulative, and synergistic effects that pharmaceutical
substances may have on both people and the environment and
should result in the elimination of the presumptive safe threshold
of 1 part per billion. The presumption that agency action routinely
will not affect the environment 95 should also be withdrawn. The
burden to prove no significant harm should be placed on
applicants for new drugs as well as those submitting modifications
to the use or formulation of currently authorized pharmaceutical
products. Moreover, the FDA should eliminate the exclusion for
substances that occur naturally in the environment 96 on grounds
that the cumulative and chronic exposure to heightened levels of
these substances, as well as exposure to these substances in
combination with other exposures, has the potential to affect
human and environmental health.
Finally, FDA's NEPA process must be amended to more
closely follow the statute's original procedures designed to
obligate the federal government to incorporate environmental
concerns into the decision-making process prior to undertaking
any action. 197 FDA should revise its regulations (21 C.F.R. §
25.52(a)-(b)) to ensure that EISs are subjected to public
dissemination and notice-and-comment, prior to the agency taking
193 National Environmental Policy Act; Revision of Policies and Procedures,
62 Fed. Reg. 40,570 (July 29, 1997).
194 See supra note 127-129 and accompanying text.
195 See supra note 125 and accompanying text.
196 See 21 C.F.R. § 25.31(c).
197 See supra note 120-123 and accompanying text.
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decisive action. 98 "The hope is that with an adequately informed
FDA sitting as gatekeeper to this highly profitable market, drug
design will evolve. This will lead drug companies to internalize
the external impacts of their products and, where feasible, design
drugs of the future that are noted for their minimal impact on the
environment as well as for their therapeutic effectiveness." 199
B. Drug Sale and Dispensing by Health Care Professionals
Doctors, nurses, pharmacists, veterinarians, and other health
care professionals have a tremendous impact on the use and
disposal of pharmaceutical products. Prescription drugs, for
example, cannot reach the final user without going through a
healthcare provider.
Accordingly, all health care professionals involved in
dispensing and administering drugs should be educated and
specially trained to instruct their patients and customers on the
safe use and disposal of pharmaceutical products. This includes
information on proper dosing, whether to take with or without
food or water, and dose spacing to maximize efficacy and sorption.
Training should incorporate information on the proper disposal of
unspent and expired medication that includes proper disposal
techniques and location of approved collection sites.200
Additionally, it should encompass information on possible
alternatives to the use of pharmaceuticals, including natural and
non-pharmaceutical products and those with less harmful residues,
as well as preventative health care options that would reduce the
need for medication.20 Training and education of health care
professionals could be achieved through continuing education
licensing requirements for individual doctors, nurses, pharmacists,
198 See supra note 136-138 and accompanying text.
199 Christopher T. Nidel, Regulating the Fate of Pharmaceutical Drugs: A
New Prescription for the Environment, 58 FOOD & DRUG L.J. 81, 100 (2003)..
200 See Kummerer, supra note 26, at 415 ("Proper information for doctors,
pharmacists and patients can contribute to the reduction of the input of APIs into
the aquatic environment .... Proper information on how to handle leftover
drugs will result in the reduction of the environmental burden of drugs.").
201 For example, Daughton suggests that nutrition and health maintenance
programs can reduce the incidence of diseases and, thereby, reduce the release of
PPCPs associated with the treatment of those diseases. See Daughton, supra note
166, at 777. Daughton further suggests consideration of drug alternatives, such
as probiotics that can block pathogen adhesion, and that may achieve the same
therapeutic results without the attendant drug execration or disposal problems.
Id.
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and veterinarians, as well as licensing and certification criteria for
health care institutions. It also could be integrated into the degree
granting criteria for these professions. Ultimately, though,
ensuring minimum standards and consistency in health care
provider knowledge and patient education may require regulatory
intervention.
C. Consumer Use
Consumers and end users should also be educated on the safe
use and disposal of pharmaceutical products, as well as on
alternatives and preventative health care options. In particular,
consumers need to be educated on the potential impact of
pharmaceutical pollutants reaching the environment through
improper disposal and excretion.
Drug education may be especially prudent for certain
dangerous drugs, such as those listed in Schedule II of the
Controlled Substances Act (CSA), 202 as part of an effort to ensure
safe use and disposal. While such a program may be difficult to
impose on the general public, it could be implemented through
FDA regulations as a. requirement for the use of these powerful
pharmaceuticals. Nevertheless, requiring the public to undertake
training for all prescription medication clearly would be a
tremendous challenge and a likely barrier to the provision of
appropriate health care. Accordingly, consumer education should
be pursued as a government-led public service initiative and
undertaken collaboratively with the pharmaceutical industry,
health care professionals, public health and safety institutions,
professional associations and non-governmental organizations
specializing in human or environmental health issues, and other
relevant entities. Educational efforts can include: brochures and
other written material supplied by manufacturers and health care
professionals in conjunction with the distribution of
pharmaceutical products and health care services; direct
conversations between health care professionals and consumers;
public service announcements transmitted by radio, television,
movie theaters, and other media; and public education advertising
202 Drugs listed in Schedule I! of the CSA include drugs with a high potential
for abuse that may lead to severe psychological or physical dependence, but
which also have a currently accepted medical use in treatment in the United
States. 21 U.S.C. § 812(b)(2).
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campaigns.
D. Product Disposal
Drug disposal in the United States is, at best, haphazardly
managed and regulated. For example, while the FDA recommends
disposal of dozens of pharmaceuticals by flushing them down the
toilet, EPA urges the public never to flush expired or unwanted
prescription and over-the-counter drugs unless the product label
specifically advises such disposal .203 While the two approaches are
not mutually exclusive, the FDA flushing recommendation is
based primarily on potential misuse and overuse concerns rather
than post-disposal human and environmental hazards. 204
Moreover, FDA sanctioning of flushing for some pharmaceuticals
could easily be misconstrued as applicable to all household
medicines. 20 5
Furthermore, while RCRA applies to any facility that
generates more than one hundred kilograms of hazardous
pharmaceutical waste per month, 20 6 the statute appears to be only
minimally enforced against health care providers and facilities. 20 7
Moreover, while the assortment of take-back projects implemented
by DEA, states, and various local governments are laudable, the
lack of funding and consistency among the programs constrains
their efficacy. Yet, given the astonishing quantities of
pharmaceutical products collected through the various DEA and
203 Compare Disposal of Unused Medicines: What You Should Know, U.S.
FOOD & DRUG ADMIN. (advocating disposal of numerous pharmaceuticals by
flushing them down the toilet), http://www.fda.gov/Drugs/ResourcesForYou/
Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisp
osalofMedicines/ucml86187.htm (last updated Feb. 10, 2015), with ENVT'L
PROT. AGENCY, EPA 816-F-1 1-003, How TO DISPOSE OF MEDICINES PROPERLY
(2011) (admonishing against the disposal of expired or unwanted prescription
and over-the-counter drugs down the toilet or drain unless the product label or
accompanying patient information specifically directs such disposal), available
at http://water.epa.gov/scitech/swguidance/ppcp/upload/ppcpflyer.pdf.
204 See How to Dispose of Unused Medicines, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/forconsumers/consumerupdates/ucm101653.html
(last updated Aug. 19, 2014).
205 Cf Marvin E. Herring et al., Current Regulations and Modest Proposals
Regarding Disposal of Unused Opioids and Other Controlled Substances, 108 J.
AM. OSTEOPATHIC ASs'N 338, 341 (2008) (discussing the "disposal dilemma"
facing patients and health care providers as a result of ambiguous and often
inconsistent drug disposal recommendations at the state and federal levels).
206 See 40 C.F.R. § 261.5(a); see also supra text accompanying note 74.
207 See supra notes 77-78 and accompanying text.
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state and local programs, 208 the demand and need for such
programs is undeniable.
1. Reverse Distribution
Hospitals, clinics, pharmacies, doctor offices, and other health
care facilities are often left with significant quantities of unsold,
expired, damaged, recalled, or discontinued pharmaceutical
products.20 9 These products are usually disposed through the waste
stream 210  and occasionally through authorized donation
programs. 21' Many of these entities also have the option of
returning these drugs through a reverse distribution system.
Reverse distribution refers to a process by which authorized
companies recycle or dispose of unused and unsold expired,
damaged, recalled, or discontinued pharmaceutical products
obtained from wholesaler, distributor, pharmacies, and
hospitals. 212 This subset of the pharmaceutical industry emerged to
208 See supra notes 151-152, 169, 172-74 and accompanying text.
209 While few health care facilities keep track of the quantities of
pharmaceutical waste generated, a 2008 sampling by the Associated Press
suggested that the volume of pharmaceuticals and contaminated packaging
generated in the United States annually exceeded 250 million pounds. See Jeff
Donn et al., AP IMPACT.- Health Care Industry Sends Tons of Drugs into
Nation's Wastewater System, ASSOCIATED PRESS (Apr. 14, 2008),
http://hosted.ap.org/specials/interactives/pharmawater-site/septl4a.html. A 2003
survey of sixty primary doctor's offices, health care and veterinary centers, and
hospitals in King County, Washington showed that these facilities disposed of
nearly four thousand pounds of medical waste annually through hazardous waste
vendors, reverse distributors, and municipal trash disposal, and dumped down
drains or toilets an additional 10,610,644 milliliters of liquid medication (e.g.,
narcotics, cough syrup, injectable liquids, and IV liquids) and 6,188 pills and
tablets. See D. OLIVER & A. CHAPMAN, LOCAL HAZARDOUS WASTE
MANAGEMENT PROGRAM, PHARMACEUTICAL WASTE SURVEY 11 tbl.9 (2003),
available at http://www.lhwmp.org/home/publications/publicationsdetail.aspx?
DoclD=zl8Wbqv9QSk%3d.
210 Donn et al., supra note 209 (reporting on the finding of an Associated
Press investigation that revealed that "U.S. hospitals and long-term care facilities
annually flush millions of pounds of unused pharmaceuticals down the drain,
pumping contaminants into America's drinking water... ").
211 Kevin B. O'Reilly, Charity Helps Medical Practices Donate Unused
Drug Samples, AM. MED. NEWS (Aug. 22, 2012), http://www.amednews.com/
article/20120822/profession/308229996/8/.
212 Reverse distributor is defined in 21 C.F.R. § 1300.01(b) as:
a registrant who receives controlled substances acquired from another
DEA registrant for the purpose of-
(1) Returning unwanted, unusable, or outdated controlled substances to
the manufacturer or the manufacturer's agent; or
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facilitate manufacturers' return policies for potential credit for
unsold pharmaceutical products. 213 As a secondary objective,
reverse distribution is now accepted as a mechanism for
minimizing the likelihood that these products would be diverted
for illicit use.2 14
With the recent adoption of DEA's new rules, reverse
distributors are now authorized to administer consumer mail-back
programs and maintain collection receptacles for consumers'
unused, unwanted, and expired pharmaceutical products.215
Although the justifications for the rule change might still
emphasize law enforcement objectives, to the extent that the
efforts reduce the volume of drugs that are improperly circulated,
used, or discarded, the outcome could also have a beneficial
impact on human and environmental health.
2. Pharmaceutical Take-Back Programs
Federal and state governments should make greater efforts to
organize, promote, and fund drug disposal and collection
programs. Whether structured through designated drop-off
locations or through a mail-in process, these programs should be
developed to maximize the collection and proper disposal of
unused, unwanted, and expired pharmaceutical products. Two
challenges, however, must be overcome to facilitate the
development and expansion of such programs.
The first challenge relates to the CSA and DEA regulations
that, until recently, effectively prohibited consumers ,and health
care institutions that were not registered with the DEA (e.g., many
nursing homes and other long term health care facilities) from
transferring possession of dispensed controlled substances to
anyone other than a law enforcement official.216  While
(2) Where necessary, processing such substances or arranging for
processing such substances for disposal.
Reverse distributors currently are not permitted to accept controlled substances
from consumers, doctors, and others not authorized by the DEA. See
Amendment to the Universal Waste Rule: Addition of Pharmaceuticals, 73 Fed.
Reg. 73,520, 73,533 n. 45 (Dec. 2, 2008).
213 See Johnson, supra note 155, at 3; Amendment to the Universal Waste
Rule: Addition of Pharmaceuticals, 73 Fed. Reg. at 73,525.
214 See Amendment to the Universal Waste Rule: Addition of
Pharmaceuticals, 73 Fed. Reg. at 73,525.
215 See supra note 148-150 and accompanying text.
216 Amendment to the Universal Waste Rule: Addition of Pharmaceuticals,
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maintaining control over these dangerous drugs is an important
law enforcement objective, 217 creating more opportunities for
proper disposal in a secure manner could serve both law
enforcement and human and environmental health objectives.
As noted above, in September 2014, DEA issued new
regulations expanding the options available for collecting
controlled substances from ultimate users, including reverse
distribution, through take-back events, mail-back programs, and
collection box locations. 218 While the new rule does purport to
expand opportunities for the disposal of unused prescription
medication, the rule's impact is unlikely to be significant in terms
of removing unused pharmaceuticals from circulation and,
thereby, decreasing their introduction into the environment. The
rule's chief shortcoming is that rather than mandating specific
mechanisms for the proper disposal and collection of these
pharmaceuticals, it merely authorizes the pharmaceutical industry
to voluntarily undertake such programs. 219 Moreover, it imposes
both the costs associated with program implementation, 220 as well
as liability for theft, improper diversion, and other illegal conduct
73 Fed. Reg. at 75,785, 75,787. It is noteworthy that the CSA and DEA
regulation do not explicitly prohibit such transfers. Nevertheless, the Act and the
regulations have no provisions that explicitly authorize a DEA registrant (such as
a pharmacy) to receive and accept a controlled substance from a non-registrant or
individual end-user. BRIAN T. YEH, CONG. RESEARCH SERV., R40548, LEGAL
ISSUES RELATING TO THE DISPOSAL OF DISPENSED CONTROLLED SUBSTANCES 10
(2010). Moreover, the CSA expressly prohibits consumers from engaging in the
"distribution" of controlled substances, which includes transferring such drugs to
anyone for disposal or .other purpose. 21 U.S.C. § 841(a)(1); Disposal of
Controlled Substances by Persons Not Registered With the Drug Enforcement
Administration, 74 Fed. Reg. 3481 (Jan. 21, 2009). Accordingly, "if the CSA
does not explicitly permit an action pertaining to a controlled substance, then by
its lack of explicit permissibility the act is prohibited." Electronic Prescriptions
for Controlled Substances, 73 Fed. Reg. 36,724 (proposed June 27, 2008).
217 The CSA's Introductory Provisions contains Congressional findings and
declarations concluding that "[t]he illegal importation, manufacture, distribution,
and possession and improper use of controlled substances have a substantial and
detrimental effect on the health and general welfare of the American people" and
that "Federal control of the intrastate incidents of the traffic in controlled
substances is essential to the effective control of the interstate incidents of such
traffic." 21 U.S.C. § 801(2), (6).
218 See Disposal of Controlled Substances, 79 Fed. Reg. 53,520 (Sept. 9,
2014); see supra text accompanying note 149.
219 See Disposal of Controlled Substances, 79 Fed. Reg. at 53,520-21.
220 Id. at 53,521, 53,551-53.
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by third parties, on the volunteers.2 2  Accordingly, absent a clear
business advantage, it is unlikely that a significant segment of the
industry will willingly assume such responsibility.
The second challenge relates to the costs associated with take-
back programs. Take-back programs generally are funded from a
variety of sporadic sources, including grants, local government
budgets, facilities generating unused, unwanted, and expired
drugs, and in-kind contributions.222 Program costs often include
collection receptacles, the presence of law enforcement,
transportation and destruction of collected drugs, as well as public
education and promotion. 223 The lack of adequate and consistent
funding to cover these expenses is a significant barrier to
developing effective pharmaceutical collection on a scale
responsive to the need. For example, a review of Wisconsin's take-
back program concluded that only a fraction of unused
pharmaceuticals were collected via take-back programs, in part,
because of "high costs [and] lack of sustainable funding. '224 The
rest "were discarded in the trash, flushed down the drain, abused,
or stored indefinitely in the medicine cabinet. '225
The most obvious source of funding for such programs is the
pharmaceutical manufacturing, distribution, and dispensing
industry. Until recently, drug manufacturers have been able to
thwart efforts to require their financial involvement.226 On
September 30, 2014, the Ninth Circuit Court of Appeals upheld an
Alameda County, California, law requiring drug manufacturers to
pay for a prescription drug collection and disposal program. 227 In
221 Id. at 53,534, 53,543-44.
222 See generally PRODUCT STEWARDSHIP INSTITUTE, supra note 165 at 8-10
(discussing the challenge of funding take-back programs, and refers to funding
mechanisms for programs in other U.S. jurisdictions as well as Canada and
Europe); MONICA HUBBARD, OREGON PHARMACEUTICAL TAKE BACK
STAKEHOLDER GROUP, FINAL REPORT 23-27 (2007), available at http:/www.
oracwa.org/pdf/oregon-drug-takeback-report.pdf (surveying various take-back
programs and referring to their funding mechanisms).
223 See UNIVERSITY OF WISCONSIN COOPERATIVE EXTENSION & PRODUCT
STEWARDSHIP INSTITUTE, supra note 174, at 53.
224 See generally id. at vi.
225 See generally id at v.
226 See Walton, supra note 169.
227 See Pharm. Research & Mfrs. of Am. v. Cnty. of Alameda, 768 F.3d 1037
(9th Cir. 2014), cert denied, 83 USLW 3865 (U.S. May 26, 2015) (No. 14-751);
see also Ed Silverman, That Flushing Sound: Pharma Must Pay for a Drug
Take-Back Program, WALL ST. J. (Oct. 1, 2014, 9:00 AM), http://
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that case, the Ninth Circuit rejected the pharmaceutical industry's
claim that the law violated the "dormant Commerce Clause" as an
unconstitutional discrimination against or burden on interstate
commerce. 228 The industry has also challenged a similar law
adopted in King County, Washington, which is broader in scope in
that it applies to all over-the-counter medications in addition to
prescription drugs. 229 Following the Ninth Circuit's decision in
the Alameda County case, King County began implementing its
new regulations.23 °
Industry-financed drug collections and disposal programs,
though, are not a novel concept. The pharmaceutical industry
funds take-back programs in Canada, France, Spain, Sweden and
Australia.231 For example, in Sweden, pharmacies are tasked by
the government with fully funding and managing the country's
take-back program for unused, unwanted, and expired household-
generated pharmaceuticals, including the safe storage and handling
of collected drugs, and promotion of the program. 232 In the
Canadian province of British Columbia, drug manufacturers are
financially responsible for the "collection, transportation, storage,
promotional activities and disposal" of their unused or expired
pharmaceutical products. 233 Given the local efforts in California
and Washington, as well as growing interest in state-level
initiatives,2 34 it remains to be seen whether the industry's
opposition to funding collection and disposal programs in the
United States can be maintained. As an incentive, some have
blogs.wsj.com/pharmalot/2014/10/01/that-flushing-sound-pharma-must-pay-for-
a-drug-take-back-program/.
228 See Alameda, 768 F.3d at 1042-43, 1045-46.
229 Complaint for Declaratory and Injunctive Relief, Pharm. Research &
Mfrs. Of Am. v. King Cnty., No. 2:13-cv-2151 (W.D. Wash. Dec. 27, 2013),
available at http://www.alston.com/files/docs/King-County-Suit.pdf.
230 KING COUNTY, WA., BOARD OF HEALTH ch. 11.50 (2010).
231 See UNIVERSITY OF WISCONSIN COOPERATIVE EXTENSION & PRODUCT
STEWARDSHIP INSTITUTE, supra note 174, at 19.
232 See id. at 54.
233 See POST-CONSUMER PHARMACEUTICAL STEWARDSHIP ASS'N,
MEDICATIONS RETURN PROGRAM: PROVINCIAL PROGRAM TO ASSIST IN THE
COLLECTION, TRANSPORTATION AND DISPOSAL OF UNUSED AND EXPIRED
MEDICATIONS FROM THE PUBLIC 9 (2006), available at http://www2.gov.bc.ca/
gov/DownloadAsset?assetld=AEABE2EBA4DA41CDAOC70F8822B4D586;
see also UNIVERSITY OF WISCONSIN COOPERATIVE EXTENSION & PRODUCT
STEWARDSHIP INSTITUTE, supra note 174, at 54.
234 See Walton, supra note 169.
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recommended providing drug manufacturers patent extensions and
other inducements for implementing effective drug collection,
disposal, recycling, or other stewardship programs. 235
CONCLUSION
In May 2014, British headlines scandalized readers with a
United Kingdom governmental finding that cocaine use in Britain
had become so pervasive that its metabolite, Benzoylecgonine,
was now found in that nation's drinking water supplies. 236 While
most journalists focused on the sensationalist aspects of the story,
the presence of the drug in the drinking water supply of a highly
developed Western nation should raise more poignant questions,
including: how did the pernicious substance get into the public
drinking water supply; why did the wastewater and drinking water
235 See e.g., Daughton, supra note 166, at 776; Herring et al., supra note 186,
at 341.
236 See e.g., Ben Spencer, Cocaine Use in Britain So Widespread It Can
Be Found in our DRINKING WATER, DAILY MAIL, May 12,
2014, http://www.dailymail.co.uk/news/article-2625659/Cocaine-use-Britain-
widespread-DRINKING-WATER.html; Adam Withnall, Cocaine Use in Britain
So High It Has Contaminated Drinking Water,. Report Shows, INDEPENDENT,
May 12, 2014, http://www.independent.co.uk/news/uk/home-news/cocaine-
use-in-britain-so-high-it-has-contaminated-our-drinking-water-report-shows-
9350477.html. The British scenario is not an outlier. Illicit drugs have also been
found in municipal wastewater discharges in the United States, as well as various
continental European nations. For studies in the United States, see e.g., Caleb J.
Banta-Green et al., The Spatial Epidemiology of Cocaine, Methamphetamine and
3,4-methylenedioxymethamphetamine (MDMA) Use: A Demonstration Using a
Population Measure of Community Drug Load Derived from Municipal
Wastewater, 104 ADDICTION RES. REP. 1874, 1875 (2009) (describing a study in
Oregon where researchers were able to conclude that cocaine use was much
higher in cities while methamphetamine was popular in all areas based on testing
of wastewater from 96 Oregon municipalities); Shannon L. Bartelt-Hunt et al.,
The Occurrence of Illicit and Therapeutic Pharmaceuticals in Wastewater
Effluent and Surface Waters in Nebraska, 157 ENVTL. POLLUTION 786, 786
(2009) (discussing the "occurrence and estimated concentration of twenty illicit
..and therapeutic pharmaceuticals and metabolites in surface waters influenced by
wastewater treatment plant ... discharge and in wastewater effluents in
Nebraska... "). For studies in Europe, see e.g., Maria Huerta-Fontela et al.,
Occurrence of Psychoactive Stimulatory Drugs in Wastewaters in North-Eastern
Spain, 397 SCI. TOTAL ENV'T 31 (2008); Sara Karolak et al., Estimation of Illicit
Drugs Consumption by Wastewater Analysis in Paris Area (France), 200
FORENSIC SCI. INT'L. 153 (2010); Carla Repice et al., Licit and Illicit Drugs in a
Wastewater Treatment Plant in Verona, Italy, 463 Sci. TOTAL ENv'T 27 (2013);
Senka Terzic et al., Illicit Drugs in Wastewater of the City of Zagreb (Croatia)-
Estimation of Drug Abuse in a Transition Country, 158 ENVTL. POLLUTION 2686
(2010).
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treatment systems not eliminate it; what other pharmaceutical
pollutants might be lurking in the water; and, more importantly,
what might be the human and environmental consequence of the
presence of such substances in the environment?
The reality today is that pharmaceuticals, both licit and illicit,
and their components and residues are ubiquitous in soils, rivers,
lakes, and aquifers across the globe. Moreover, the evidence is
quite good that these substances are having an adverse impact on
aquatic and other species and may similarly be affecting human
health.
Despite the growing concerns, there is presently a dearth of
political and regulatory attention focused on this situation. In the
United States, neither the federal nor the various state
governments have adopted any policy, legislation, or
comprehensive programs designed to respond to the growing
threats posed by this situation, and the existing environmental and
drug-related regulations and programs have been, at best,
disorganized and ineffective. While the federal and a handful of
state governments have issued a number of significant citations for
violation of existing law,2 37 that effort should not be confused with
an effective regime for managing or preventing the presence and
237 For example, in 2003 and 2004, EPA Region 2 issued fines under RCRA
ranging from $40,000 to $280,000 after identifying violations at a number of
health care facilities. EPA-OIG 2012 REPORT, supra note 84, at 10. In 2009, EPA
Region 7 issued a hospital a $51,501 RCRA fine and required the facility to
implement programs to manage pharmaceutical and other waste at a cost of
nearly $500,000. See Johnson, supra note 155, at 1; Large EPA Settlement Points
to Common Problems with Hazardous Waste, HOSPITAL SAFETY INSIDER (Nov.
18, 2009), http://www.hcpro.com/SAF-242333-874/Large-EPA-settlement-
points-to-common-problems-with-hazardous-waste.html. At the state level, in
2010, the New York Attorney General settled with five health care facilities after
investigations showed they violated the federal SDWA by released releasing
pharmaceutical waste into the New York City watershed. See Product
Stewardship for Drug Manufacturers, N.Y. STATE SOLID WASTE EXAM'R
(Legislative Comm. on Solid Waste), Fall 2011, at 9. In April 2012, California
settled with retail drugstore giant, CVS Pharmacy, for $13.75 million on claims
that the national chain illegally disposed of pharmaceutical and other hazardous
waste in violation of California's hazardous waste laws. Sarah Rohrs, CVS Retail
Giant Must Pay $13.75 Million in Fines Over Waste Disposal Violations,
VALLEJO TIMES HERALD, Apr. 19, 2012,, http://www.timesherald
online.com/ci_20431774/cvs-retail-giant-must-pay-13-75-million. Two months
later, California settled with Costco for $3.6 million on similar allegations of
state law violations. Costco to Pay $3.6M Settlement, RECORDNET.COM (June
5, 2012), http://www.recordnet.com/apps/pbcs.dll/article?AID=/20120605/a-biz/
206050307.
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fate of pharmaceuticals in the environment.
The recommendations proposed here all focus on the early
stages in the pharmaceutical lifecycle, which would reduce the
likelihood that pharmaceutical pollutants actually reach the
nation's soils, rivers, lakes, and aquifers. These options are not
meant to prioritize environmental considerations over the health
benefits derived from modem medicine. Rather, they are offered
as strategies for improving the design, approval, manufacturing,
distribution, use, and disposal of pharmaceuticals in ways that both
ensure their continued safe use and prevent them from causing
unintended harm to people and the environment. While pursuing
such strategies could increase the costs of pharmaceutical
products, consumers and the general public are already paying a
price in the form of environmental harm and possible health
effects. Eventually, the public might also have to pay for enhanced
wastewater and drinking water treatment operations.
There is no single culprit responsible for pharmaceutical
pollutants reaching our nation's waters and environment.
Manufacturers produce the products; consumers readily ingest or
absorb them and then excrete them into the environment. In
between, drug distributors, pharmacies, and health care providers
route and dispense these substances, while miscreants divert them
for illicit purposes. In order to not only reduce existing known
threats but also minimize potential hazards, an approach for
addressing pharmaceutical pollutants requires the involvement of
all stakeholders, such as local communities, health care providers,
environmental organizations, the pharmaceutical industry, law
enforcement officials, and state and federal regulatory agencies
and legislators.
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